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Abstract: Biodegradable polymers are promising materials for use in medical applications such as
stents. Their properties are comparable to commercially available resistant metal and polymeric
stents, which have several major problems, such as stent migration and stent clogging due to microbial
biofilm. Consequently, conventional stents have to be removed operatively from the patient’s body,
which presents a number of complications and can also endanger the patient’s life. Biodegradable
stents disintegrate into basic substances that decompose in the human body, and no surgery is
required. This review focuses on the specific use of stents in the human body, the problems of
microbial biofilm, and possibilities of preventing microbial growth by modifying polymers with
antimicrobial agents.
Keywords: stent; biodegradable polymer; polylactide; antimicrobial agents; antimicrobial
effects; medicine
1. Introduction
The human body has a complex structure, where each organ has an important task. Body
organs are composed of various cell types, extracellular matrices, proteins, and other macromolecules.
The organs are supplied with body fluids that are transported by passive diffusion processes or tubular
organs. These tubular organs differ in the structure of epithelial cells being adapted to the liquid or
solid contents that flow through the tube, such as blood, bile, food, fluids, etc. [1,2]. Diseases of blood
vessels and other body ducts are a considerable problem of contemporary medicine. Severe illnesses
cause their narrowing and clogging and the patients suffer from severe pain [3]. One of the possible
solutions to this problem is the use of stents. Stents are small tubes made of metal or polymer usually
used for restoring the passage of blood vessels or ducts. They also have a wide range of uses in other
parts of the body. According to their location in the body, they can be divided into coronary and
vascular, esophageal, duodenal and other intestinal ducts, biliary, pancreatic, ureteral and prostate, or
drug stents [4–10].
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One of the main complications in the use of stents is the formation of microbial biofilm on their
inner surface. In particular, bacteria irreversibly adhere to the surface of medical objects, creating a
biofilm that causes severe infection. The biofilm resists immune protection system and antibiotics
therapies, and it can cause serious illness or even lead to the death of patients. There are several
possibilities for how to prevent a bacterial adhesion and growth on the surface of medical devices.
One of them is to prepare a material on which bacteria and other microorganisms are not able to
adhere and develop into the biofilm. Currently, materials based on polymer composites or polymers
with surfaces modified with an antimicrobial agent are studied for their efficiencies to prevent biofilm
growth. In addition, other options based on physical surface properties such as surface roughening,
or vice versa smooth surface, super hydrophobic, etc. were designed to prevent bacterial adhesion.
This review is focused on the research and development in medical stents, especially biliary stents,
and on the possibilities of the use of new materials for stent production to increase their ability to resist
microbial contamination and increase the quality of their utility properties. It consists of three parts:
(i) the first part focuses on the overview of stents used in medical applications and also on problems
arising from biofilm formation, (ii) the second part is focused on biliary stents and (iii) in the third part
new possibilities for stent production preventing microbial growth are discussed.
2. Stents
2.1. The Principle of Stents
Stents are used for restoring the patency of a blood vessel and other ducts in the body. When
an obstruction is created in a duct, blood or other body liquids cannot flow properly. In that case, an
endoscopically inserted stent is used. When an expandable stent is used, it is often inserted with a
balloon that is inflated after the stent has been correctly positioned, and then the stent is stretched to
the desired width. A schematic representation can be seen in Figure 1.
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2.2. Types of Stents
There are nine major types of stents that are divided by location in the human body (Figure 2):
Coronary and vascular, esophageal, duodenal, biliary, pancreatic, ureteral, prostate and drug stents.
Stents can be made of three materials: (i) metals, (ii) permanent polymeric materials and iii)
biodegradable polymeric materials. The type of material is selected according to the location of
the stent in the human body and according to the duration of its action. The material choice also
depends on the cost of the stent. Currently, efforts are being made to replace metal stents by
biodegradable polymer stents. The disadvantages of metal stents are their easy clogging, stent
migration in the human body, cell ingrowth into the stent and restoration of stenosis, problems during
some special medical examinations such as MRI (Magnetic Resonance Imaging) and the high price
of stent. These problems may also occur in case of use of permanent polymer stents. The main
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complication of stents made from permanent materials is a surgical intervention to remove the stent
as surgery can endanger a patient’s life [11–14]. For this reason, new possibilities of manufacturing
and modifying materials are being studied to reduce the risk to the patient. Biodegradable stents
disintegrate into essential components that the human body can safely break down and eliminate. In
addition, various antibacterial agents are used to modify polymeric materials to reduce the risk of
infection and biofilm formation on the stent surface and consequently stent clogging [12].
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r i sc l r diseases are the most prevalent diseases in the world. In 2015, 40% of all mortality
was caused by a cardiovascular and circulatory system disease [15,16]. The main cause of these diseases
is the deposition of fat and cholesterol in the coronary artery walls. Fat and cholesterol can block
the coronary vessels. This problem is solved by angioplasty, during which a balloon catheter is used
which inflates at t e stenosis site. The balloon compresses the plaque on the walls of the coronary
arteries, and after its remov l ensures the conti uous flow of blood. The role of the stent in that case is
to mai tain blood flow [17]. The first coronary stent was made in the late 1980s. Since t n, coronary
stents ave developed very rapi ly. Th y are classified into thr e main groups: Bare metal stents
(BMS), drug- luting stents (DES) and bioresorbable vascular scaffolds (BRS) [6,18–21].
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Bare metal stents (BMS) have been produced since 1986, and were first manufactured from
stainless steel. Currently, cobalt-chromium, platinum-chromium or other alloys have largely replaced
stainless steel. An ideal BMS should have good deliverability, flexibility, low thrombogenicity and
good biocompatibility [18].
Drug-eluting stents (DES) are relatively new in medicine. The first models (first phase models) were
applied in 1999. They had a more complex structure as they gradually released a drug. They consist
of a metal part and a polymeric cover which contained a drug (Myolimus, Novolismus and other
antiproliferative drug). However, the polymeric coating is one of the causes of the pathogenesis of
long-term stent failure by inducing a potential chronic inflammation [18].
The further models (second phase models) use biodegradable polymers or bioresorbable materials
in combination with metal stents. The most widespread biodegradable polymers for drug-eluting stents
are poly-L-lactic acid (PLLA) and its copolymers (such as poly-DL-lactide-co-glycolide). The polymer
contains a drug, which is gradually released. After degradation of the biodegradable polymer in its
early phase, the metallic platform of the stent remains in the coronary artery. The polymer degrades to
low molecular weight substances that are excreted from the body. The polymers used must be well
characterized because when mixed with another polymer, the molecular weight, structure, and other
physical and chemical conditions affect the polymer degradation time and its biocompatibility [22,23].
The first clinically available polylactide stent was manufactured by the company Abbott in 2011 and
was approved by the FDA in July 2016. It was made from PLLA and was called "ABSORB 1.0".
ABSORB 1.0 was described as a temporary scaffold for the treatment of ischemic heart disease. The first
generation of ABSORB 1.0 had a zigzag structure with a cross profile of 1.4 mm and strut thickness of
150 µm [24].
The second generation of ABSORB 1.0 was called "ABSORB 1.1". The stent had many shared
features with the first generation. However, the stent manufacturing process was different. The polymer
was blow into a mold to provide it with prolonged radial support [25]. The company Abbot is trying
to develop a thinner reinforcing stent, which will be named "Falcon" and its strut diameter will be less
than 100 µm [26,27].
In 2013, another company, Elixir Medical, developed their first stent called "DESolve 150".
This stent was bioresorbable polylactic acid (PLA) based and it had strut thickness of 150 µm
incorporating 2 platinum-iridium markers at both ends [28,29]. The main difference between DESolve
and ABSORB was its ability of intrinsic radial expansion, which also provides a greater tolerance
to overexpansion for DESolve. The skeleton of DESolve was coated by PLA, and this PLA coating
was impregnated with Myolimus, which is an antiproliferative drug that inhibits the growth of a
cell. This stent is resorbing within 12–24 months through hydrolysis [30,31]. The next steps of Elixir
Medical were in the development of stents with lesser strut profile. In 2014, they introduced the
DESolve 100, a stent with a strut profile of 100 µm, and degradation time within one year. It is fully a
biodegradable PLLA-based stent that elutes Novolismus with anti-proliferative and anti-inflammatory
properties [28,32]. Currently, they are working on new DESolve Cx stents with an average strut
thickness of 120 µm and DESolve NTx stents which are third-generation vascular stents [33].
Meril Life Sciences (City, India) has tested the efficacy of its biodegradable stent in an experimental
animal study [34,35]. The stents were made from PLA, and its strut thickness was smaller than 200 µm.
The stent released Sirolimus over 90 days with a dosage 1.25 g/mm2. Three platinum markers were
inserted into the stent for a better tracking of the stent placement in the body [36].
Vascular and coronary stent insertion is accompanying with the risk of microbial biofilm formation,
which can cause serious infectious diseases. Another risk of coronary stents is cell ingrowth into the
stent and restoration of stenosis [37,38].
2.2.2. Esophageal Ducts
Malignant and benign esophageal diseases are a serious problem in which the esophagus narrows.
Food and fluid are difficult to get into the stomach, and the patient suffers from severe pain. The main
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disease that affects the esophagus is cancer [39]. This cancer causes a rapid death; only less than
20% of patients with this disease will survive more than five years. Esophageal stents are a good
solution for patients because this palliative treatment allows per-oral drinking and feeding, as well
as the swallowing of saliva [40]. For the treatment of malignant and benign esophageal diseases,
self-expanding polymer stents (SEPS) and self-expanding metal stents (SEMS) are used. SEPS have
several advantages over SEMS. They are cheap, their placement is easy, and they do not induce a tissue
reaction [8,41,42]. However, polymeric stents have a high migration rate to the remaining digestive
tract [43].
For that reason, the SEMS are currently used for the treatment of malignant esophageal obstruction.
They have a mesh structure that helps to self-expand after stent insertion in the esophagus, and,
consequently, it restores passage of the esophagus. The use of SEMS is frequent, but these stents have
some complications, which are caused only by the mesh structure of the stent. Such a structure does
not prevent the new tissue from growing through the mesh, which then grows through the stent and
can bleed [43]. This leads to a risk to a patient’s life and the stent must be surgically removed.
Biodegradable polymeric stents can be one of the solutions to this problem. They are made
of polylactide or polydioxanone [44–46]. These types of stents will also be useful for patients with
temporary esophageal injuries or esophageal cancer patients, since the stent disintegration time may be
affected by the stent chemical composition. Biodegradable polymeric stents need not be removed even
after migration to another part of the digestive system, and have shown good results in the treatment
of benign esophageal strictures [47].
2.2.3. Duodenal and Pancreatic Ducts
Pancreatic cancer is one of the diseases that usually leads to the death of a patient. This cancer can
be treated by surgical resection at an early stage, but more than 80% of patients are diagnosed at an
unresectable stage [48]. Carcinoma of pancreatic, stomach, duodenum, or proximal jejunum can cause
gastric outlet obstruction (GOO). This complication occurs in 10–20% of cases of pancreatic-biliary
cancer [10,49]. GOO is treated either by a surgical gastrojejunostomy or by endoscopic duodenal
stenting, which was first reported in the early 1990s. The latter method is a non-invasive treatment
option for GOO patients. Both methods were compared, and studies revealed no differences in
the incidence of adverse events and the overall survival between them. Endoscopic stenting has
some advantages: A shorter hospital stay, and less strain on the body than gastrojejunostomy.
Some studies indicate that a stent with chemotherapy treatment can extend a patient’s life by up
to three months [10,50–52]. Another gastrointestinal area where stents are used is the small bowel,
or they can be applied for the treatment of colorectal cancer due to intestinal strictures, which are
complications of enteral diseases [53,54].
Currently, the treatments of pancreatic diseases are continuously evolving. Pathological conditions
are treated using endoscopic therapy. One method of endoscopic therapy is an insertion of a pancreatic
stent. Pancreatic stents are important for the treatment of recurrent idiopathic pancreatitis, chronic
pancreatitis, pseudocysts, pancreatic fistulae and main pancreatic duct injuries, complications of
acute pancreatitis, and in the prevention of post-endoscopic retrograde cholangio-pancreatography.
Pancreatic stents are usually used to treat obstructing stones using bypass or to treat intraductal
hypertension and for restoring lumen patency in cases where major pancreatic duct has been
disrupted, in dominant symptomatic constrictions, in fluid collections or drainage pseudocysts,
to treat symptomatic major or minor papilla sphincter stenosis, and to prevent procedure-induced
acute pancreatitis [9]. Pancreatic stents vary greatly depending on the type of treatment. Stents differ
in shape and material from which they are made. Currently, self-expanding metal stents are the most
commonly applied; however, they have several disadvantages including the stent occlusion together
with inward or outward migration and anatomic changes of the pancreatic duct. These problems limit
their long term use [55].
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2.2.4. Biliary Ducts
One of the current problems of gastro medicine is the benign stenosis of biliary tracts. The benign
stenosis is manifested by a narrowing of the bile ducts or even biliary obstruction. Strictures are the
result of injuries to the bile ducts, gallstones, chronic inflammatory disease, gallbladder surgery, or
gallbladder cancer [56–60]. Biliary obstruction may also occur as a result of pancreatic cancer. It is a
very serious illness that is manifested by jaundice and itching, but occasionally may progress to biliary
sepsis secondary to cholangitis and also causes severe pain to patients. The solution to this problem is
the use of stents that pass through the bile duct; however, a formation of biofilm in combination with
a high density of biliary fluids is a common complication when they are used. This problem is the
subject of this review, and a separate chapter is devoted to biliary stents [61,62].
2.2.5. Ureteral Ducts
First generation ureteral stents were made from silicone, which was replaced by polyethylene, but
polyethylene becomes unstable in urine and leads to fractures. Gradually, stents have been improved
and currently two-layer stents from polyurethane are being used. Ureter stents are used to prevent
ureteral obstruction, to facilitate the passage of stone fragment, and to prevent delayed ureteral stricture
formation [63]. Ureteric stents are used primarily for pain relief at an obstruction. Ureteric stents have
some disadvantages such as infection, pain drainage failure, dislodgment, frequent urge to urinate,
and migration. These problems can cause damage to the kidneys or their failure. There is not currently
an ideal ureteric stent [64] since they are very favorable for the adhesion of microorganisms and
subsequent biofilm formation. Biofilm clogs the stent and this leads to widespread infection and sepsis.
It is very resistant to antimicrobial agents [65].
2.2.6. Prostatic Ducts
Benign prostate hyperplasia (BPH) is a benign prostate enlargement associated with aging that
can lead to urinary disorders. This problem is being treated with a transurethral resection of the
prostate (TURP). This treatment involves surgery, which is often risky in older patients and therefore
permanent catheterization is the only alternative. The prostatic stents are an alternative to conventional
surgical therapies and restore urine flow by maintaining the prostate lumen [66]. Prostate stents
can be divided into temporary and permanent. Temporary prostatic stents keep the lumen of the
urethra open and are not incorporated into the urethra wall. Non-absorbable and biodegradable
materials are used to produce prostate stents. Stents are made of stainless steel, nitinol, polyurethane,
polyglycolic, or polylactic acid. Non-absorbable stents must be withdrawn between 6–36 months.
The first generation of prostatic stents were made from stainless steel and were called Urispiral and
ProstaKath [67]. The incidence of complications in these stents was significant. The most common
complications being stent migration, recurrent urinary infection, and hematuria with urinary retention
due to the formation of clots and incrustations [68]. The development of modern materials brought
stents of second generation that are made from nitinol and polymeric material such as polyurethane,
polylactide, and copolymers of polylactide with polyglycolic [69]. Permanent stents were initially
developed for vascular and coronary applications and were later adapted for urology. The urethral
wall grows through the stent. This process reduces the risk of urinary infections and migration but has
the disadvantage of a difficult removal, if necessary [70]. Prostatic stents are susceptible to biofilm
formation as ureteral stents.
3. Biofilms
As mentioned above, the most common problems of stents are due to their clogging due
to the formation of biofilm and adhesion of biological substances that pass through the stent.
Biofilm represents the most widespread way of microbial growth in nature and is critical for
the development of clinical infections. It is produced by bacteria and host products [71,72] that tend to
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adhere to different surfaces. They create huge colonies known as biofilms. Existence in biofilms is for
them more advantageous because biofilm provides protection for their cells, maintains a homeostasis,
and creates a barrier that isolates bacteria from the surroundings. There is extensive communication
between bacteria and the effective horizontal transfer of resistance and virulence genes that make
bacteria very resistant. Thus, bacteria cells in biofilm are more resistant to toxic substances, UV
radiation, mechanical damage, bacteriophages, or predators. They are also more resistant to the
immune system and antibiotics in a human or animal body [73]. The surface of the material is very
quickly occupied by bacteria because the host products create a biofilm on the material that helps to
bind the bacteria. This process takes place in five stages, as can be seen in Figure 3 [74].
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Biofilms affect many medical applications and are a serious medical problem at the present time.
They are found, for example, in catheters, stents, contact lenses, and many other implants. Biomaterials
at risk of attaching bacteria together with corresponding body fluids and major components of the
host products for bacterial growth are classified in Table 1 [75]. The biofilm’s high resistance to
antibacterial agents results in a great risk of infection and therefore creates a very hazardous situation
for patient health [65,76]. Microbial cells that live in biofilms have greater resistance to antimicrobial
substances than cells that live alone in planktonic form [73,77]. Due to this resistance, the treatment
of biofilm infections is very difficult. Infected implants must be removed from the patient’s body.
This procedure is usually expensive and dangerous for patients because surgical procedures can cause
other complications [73,78,79]. Millions of implants and catheters are used for treatment every year.
Table 2 shows examples of implants prone to the infections of biofilms.
Table 1. Host products affecting bacterial attachment to a biomaterial [74].
Environment of the Biomaterial Su pended Liquids Main Components of the Host Products
Urethra Urine, prostatic fluid Muco olysaccharides, Tamm Horsfallproteins, glycoproteins
Cardiovas ular Bl od Seru , albumin, fibrinogen, fibronectin
Ocular Tears Proteins (lysozymes), fibrin
The oral cavity Sputum Mucopolysaccharides, glycoproteins, serumalbumin
Intestinal tract Digested food and liquids Mucopolysaccharides, glycoproteins, serumalbumin, steroids
Biliary ducts Bile Steroids, bile salts, mucopolysaccharides
Respiratory passageways Respiratory secretions Mucopolysaccharides
Bones, joints Synovial fluids, blood Serum proteins, blood elements
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Table 2. Examples of implant infections.
Implant Organisms Associated Disease References
Prosthetic valve Staphylococcus aureus, Staphylococcus albus Prosthetic valveendocarditis [80]
Contact lenses Pseudomonas aeruginosa, Staphylococcus epidermidis Keratitis [75]
Intravascular catheters Staphylococcus epidermidis, Staphylococcus aureus Septicaemia,endocarditis [81]
Urinary catheters Escherichia coli, Pseudomonas aeruginosa,Enterococcus faecalis Bacteraemia [82]
Joint replacement Pseudomonas aeruginosa, Staphylococcus epidermidis,Staphylococcus aureus
Septicaemia, device
failure [83]
Endotracheal tube Pseudomonas aeruginosa, Escherichia coli,Ureaplasma urealyticum, Staphylococcus aureus Pneumonia [84]
Biliary stents Enterobacteriaceae, Pseudomonas aeruginosa,Enterococcus, Candida albicans
Biliary obstruction,
septicaemia [85]
For this reason, new materials are being developed to reduce the risk of biofilm formation and
infection. These materials are based on polymer composites or polymers with surfaces modified with
an antimicrobial agent. In addition, other options based on physical surface properties such as surface
roughening, or vice versa smooth surface, super hydrophobic, etc. should be considered.
4. Biliary Stent
As was previously stated, biliary stents are used for the treatment of biliary obstructions. They are
very vulnerable to the formation of biofilm due to the environment in which they are used and also to
the nature of the fluid flowing through them. Thus, new antimicrobial materials are challenged to
solve the problem of biliary obstructions.
The usage of biliary stents is non-invasive and brings pain relief to patients. The procedure is often
used for the treatment of advanced irremovable tumors [86,87]. Biliary obstruction may be caused by
intrahepatic and extrahepatic causes. Intrahepatic causes are most often hepatitis, cirrhosis, or the
excessive use of drugs. Hepatitis is the inflammation of the liver, which is caused by viruses, drugs,
and alcohol. Cirrhosis is a disease that damages and disorganizes the internal structure of the liver,
and consequently it causes chronic inflammation. Drugs and anabolic steroids may cause cholestasis
and can increase the risk of developing gallstones, which are the most common cause of a biliary
obstruction. Extrahepatic causes include stone disease, cholangitis, biliary stricture, neoplasms, and
parasites. Neoplasms are tumors that cause a biliary obstruction. Cholangitis can cause carcinomas of
the biliary epithelium, gallbladder carcinomas, and carcinoma of the ampulla of Vater. Every carcinoma
causes a tapering or clogging of the biliary tracts. The standard treatment is surgery [88–90], but only
about 20% of these patients are resectable [91,92]. Patients who have unresectable tumors have a poor
prognosis of quality of life and survival [60,91,93]. Another solution for the treatment of stenosis is the
endoscopic insertion of a biliary endoprosthesis—a stent. This solution is non-invasive and also allows
other treatment possibilities such as radiation therapy, chemotherapy, etc. This method is usually
palliative, but endoscopic drainage can support the patient’s feeling of well-being [94]. Biliary stents
are produced from a polymer or metal materials [95]. They are used to restore biliary patency, they
facilitate the drainage of bile into the digestive tract, and they are applied in the palliation of malignant
biliary obstruction as well as in benign conditions such as benign biliary strictures or biliary fistulas.
Stents are classified into two types: (i) uncovered and (ii) covered. The covered stents are coated
with a synthetic or biological membrane, which prevents cell ingrowth into the stent. However, the
covered stents are associated with little flexibility and the risk of migration in the digestive tract [96].
A suitable stent for the biliary tract should have a large diameter, great flexibility, high expansion ratio,
easy delivery system, the cell should not have ingrowth into the stent, and should not need repeat
surgery [96,97].
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Since their introduction in 1979, endoscopic biliary stents have become the first choice method to
treat cholestasis for a malignant or benign biliary obstruction [95]. The success rate of this method
exceeds 90% and complications of this procedure are rare. Currently, self-expanding metal stents
are used. The wider diameter allows perfect drainage, thus reducing probability of stent clogging.
The disadvantages of metal endoprosthesis include its susceptibility to tumor ingrowth, impossibility
of removal, and its high cost. For these reasons, polymer stents are studied [98].
4.1. Biliary Obstruction
Biliary obstruction is a disease of the biliary tracts. The biliary system in the body is a system of
small ducts that connects various organs (Figure 4). It affects a significant portion of the worldwide
population. This disorder may be due to biliary stones, gallbladder surgery, chronic inflammatory
disease, or more serious diseases such as pancreatic cancer, cancer of the biliary duct, or external
compression secondary to lymph node metastasis [99].
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Figure 4. Diagram of biliary tracts.
The bile ducts lead bile from the liver and the gallbladder, through the pancreas, and into the
upper port on of the small intestine. Bile is a liver-produced fluid that helps the body digest fats. If
biliary ducts are clogged, the passage of the bile through to the intestines is hind red. Symptoms can
include burping, nausea, vomiting, a pain in the back, low pressure, cramps in the stomach, and an
attack of the gallbladder. All the diseases, which ar c used by clogged bile ducts, are dangerous for
human heal , as the liver and pancreas are key org ns without which one cannot live. In addition,
in the case of partial damage, the quality of life is significantly reduced. Risks and complicat ons of
obstructed bile duct are jaundice and liver disease, acute and chronic nflammation of the pancreas,
inflammation of the gallbladder and the bile ducts, gallblad er perforation, and perforation of the
bile ducts. I addition, obstruction jaundice can cause blood clotting disord r, decreased hepatic
function, and cholangitis. Cholangit s can have a bad nfluence on the cardiovascular system an
kidneys [99–104]. Biliary obstruction is classified into five types: (1) an ob truction is located f rther
than or equal to 2 cm from the main hepatic confluence, (2) an obstruction is located less than 2 cm
from the main hepatic confluence, (3) the ceiling of he biliary confluence is intact, right ductal system
communicates, (4) the ceiling of the biliary conflue ce is intact, left du tal system communicates, and
(5) the ceiling of the confluence is destroyed, while bile ducts are separated (see Figure 5) [105].
When the strictures are close to hepatic confluence, treatment is more difficult. Treatments of
biliary obstruction are surgery or endoprosthesis—stents. Treatment with stents is preferred over
surgery techniques because it avoids the risk of liver puncture, and it is an easier process [106].
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Figure 5. Types of biliary obstruction classified by Bismuth [105]: 1 Type: An obstruction is located
further than or equal to 2 cm from the main hepatic confluence, 2 Type: An obstruction is located less
than 2 cm from the main hepatic confluence, 3 Type: The ceiling of the biliary confluence is intact, right
ductal system communicates, 4 Type: The ceiling of the biliary confluence is intact, left ductal system
communicates and 5 Type: The ceiling of the confluence is destroyed, bile ducts are separated.
4.2. Types of Biliary Stents
Currently, biliary stents made on the basis of polymers or metals are used (Figure 6). Polymer
stents have controllable properties and are cost effective [107]. However, the use of polymeric stents is
limited by clogging, and they are only applicable for a short time. Self-supporting metal stents are
preferred for long-term use. Their disadvantage is that they are more expensive than polymer stents.
Both polymer and metal stents have a tendency to occlude with time and then must be operatively
removed. The innovative solution is a biodegradable polymer stent that disintegrates gradually [108].Nanomaterials 2019, 9, x FOR PEER REVIEW 11 of 31 
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4.2.1. Metal Stents
Self-expandable metal stents are widely recognized as an option for the palliative treatment
of patients with malignant biliary obstructions and with an expected survival of more than four
months [109]. These stents are made of either stainless steel or nitinol [110]. Metal stents are usually
preloaded in a covered polymer sheath. Stents with a diameter of around 2.7–2.8 mm are the most
frequently used [111]. When a stent is fully expanded, its diameter can reach 10 mm [112] and has a
significantly longer patency rate compared to polymer stents [113]. The biggest disadvantage of metal
stents is its cell ingrowth into the stent and emergence of restenosis and its high price [114].
4.2.2. Permanent Polymer Stents
The first use of polymer stents in 1980 was for a patient with a malignant bile duct obstruction [115].
Polymer stents are divided into two types: (i) permanent stents and (ii) biodegradable stents. They are
produced in many sizes, shapes, and lengths (3–15 cm). The most used stents are straight and pigtail
types. These stents are made of polyethylene or Teflon [116]. Most models of polymer stents are
curved to fit the contour of the common bile duct and to prevent stent migration. The first stents
were produced with side holes, but these side holes caused the creation of sludge. Permanent biliary
polymer stents for temporary use contain side flaps that are intended to prevent stent migration.
These are known as “Tannenbaum” stents and have double layers. A second layer was added to
prevent a sludge formation [117]. Sludge is a mixture of bile, blood, and occasionally bacteria that
adhere to the surface of the stent. The main problem of polymer stent use is their tendency to occlude
with time, which leads to jaundice and cholangitis. The inner surface of the stent is occluded by a
biofilm containing components of bacteria and bile [118]. The special design of Tannenbaum stents has
been used to prolong the patency. However, further randomized controlled studies did not support
these results [119–121]. Other studies have showed that the most effective method to prolong stent
patency is by inserting a stent of a larger diameter (3–3.8 mm) that remains unclogged for a significantly
longer period when compared to smaller stents (2.3–2.8 mm) [122,123]. It can be concluded that stent
diameter has a considerable effect on stent patency. The larger the stent, the longer the patency as well
as the functionality of the stent.
Polyethylene and Polyurethane Stents
Polyethylene (PE) and polyurethane (PU) stents are an alternative to metal stents, and they are
much cheaper than metal stents. The first permanent polymeric stent was introduced in the 1980s [124].
These polymers are commonly used material. However, PE and PU are not the best choice because
they are easily clogged with bile, they migrate, and they have to be removed surgically [125].
Teflon Stents
The majority of polymer stents are made of PE, PU, or Teflon. Stents made of these materials
are permanent. Their main complication is clogging, leading to the need for a timely replacement
of the stent every three to six months. Previous studies suggest that Teflon stents are better than
stents made of PE with regard to their resistance to occlusion. In addition, Teflon has a significantly
lower coefficient of friction compared to other polymers. This smoothness may impede the adhesion
of bacteria and body fluids. In one study [84], the authors focused on Teflon stent testing, in which
two types of stents with different diameters were compared. One stent was covered with antireflux
sleeve and the other stent was without an antireflux sleeve. The antireflux sleeve was intended to
prevent the backflow of the duodenal contents into the bile system. However, the achieved results
were not satisfying because, while at the beginning the patency of the stent with the antireflux sleeve
was obtained, in the next phase, the clogging occurred [126].
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Biodegradable Stents
Biodegradable stents are an attractive alternative to self-expanding stents in the treatment of biliary,
coronary, and other duct diseases. These stents can be made of biodegradable polymers [127–129].
Biodegradable polymers, such as polycaprolactone (PCL), poly(L-lactic acid) (PLA), poly(glycolide)
(PGA) (properties of the named polymers are summarized in Figure 7), and their copolymer
poly(L-lactide-co-glycolide) (PLGA), have attracted much attention due to their excellent mechanical
properties. These polymers can be used in biomedical applications, such as surgical sutures, drug
carriers, tissue—engineering scaffolds, implants for interior bone fixation, and other temporary medical
devices [130–134]. The polymers break down into basic components that are not toxic for the body.
Biodegradability time varies depending on the polymer composition.Nanomaterials 2019, 9, x FOR PEER REVIEW 13 of 31 
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Polylactide Stents for Biliary Duct
Biliary stents based on polylactide were examined, such as alternatives to metal and polymer
stents. PLA is a polymer made of lactic acid, which has two optical isomers L- and D-. The resulting
PLA can be present in one of three forms: PLLA, PDLLA, and PDLA. The stereochemistry and ratio of L-
and D-isomers influence PLA properties (Figure 8) and biodegradability. PLA with an L-isomer content
(PLLA) greater than 90% tends to be crystalline, while one with lower optical purity is amorphous [135].
PLA has good mechanical properties, such as transparency, high strength, and
biodegradability [136–138]. The mechanical properties of PLA may vary depending on various
parameters such as crystallinity, molecular weight, material formulation (plasticizers, blends,
composites, etc.) and processing. The resulting polymer may range from soft and elastic materials to
stiff and high-strength materials [139]. Thus, other chemical constituents are normally added into PLA
to adjust the properties of biliary stents. In one study [140], fibers were produced by melt spinning a
blend of PLLA and BaSO4. Fibers were braided to form a tubular mesh, and the mesh was hot-threaded
to stabilize the structure of the stent. The stent wall thickness was 0. 25 mm, the length was 50 mm, and
the outer diameter was from 6 to 7 mm when fully expanded (Figure 9). The stents were consequently
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inserted into commercial applicators for stents and applied to six pigs (group A) which had a disease of
the bile duct. After being applied, the stents opened almost immediately to their full diameter. Stents
of polyethylene were inserted into another six pigs (group B) to compare the efficiency.
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The pigs w re observed for six months, and the volume of the bile output in the drain sac was
measure daily. In group A (with biodegr dable stents), the total output of bile was significantly
smaller compared with group B ( it stents). After six months, it was sum arized that,
while the accum lation f bile in group A was about 165 mL ( edian), in group B, it was about 710 mL
(median). In both gr ups, the stents were een to be in place after three months. After six months, in
group A, the stents were ot d t cted. Th study found that the stent under investigation is s fe and
eff ctive in the treatmen of postch lecy ectom cys ic-du t leakage [140].
PLA-BaSO4 biliary stents w re also used in another study [141]. They i ti of
aticojejunal anastomosis (HJ) due to the fact hat the ap lication of the conventional method is very
difficult in a on-dilated bile duct with a median diameter less han 4 mm. They used the PLA-BaSO4
biodegrada le biliary stent for the conventi nal HJ technique performed in a non-dilated white channel
size of 7–9 mm [140,142]. Th study showed good result achieved with this m thod. Advantages can
be summarize as follows: It was not more difficult than the conventional surgical method, it did not
appear to increase the number of complications, a d it did not require any subsequent ste t removal
and used biodegradabl ma rials. The biodegradable stent method can provide sim lar he ling to a
conventi nal meth d, but us ng fewer sti ches a d easier techniques [140].
Another study [143] was aimed at the toxicity of PLA in combination with BaSO4. The chemicals
were used in a proportion 96:4 (PLA:BaSO4). Fibers of 0.3 m in diameter and 5 mm long were
prepared from this material and used for stent manufacture. Th s stent made of fibres was appli d to
male rats. The rats were nesthetized after one, three, seven, and twenty-on days after the cati ns,
nd hi tological and pathological t sts w e carried out. No histological cha ges were observed.
The study found that the m terial used was no more toxic than the reference steel material [143].
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In another study [144], the degradation behavior of biodegradable polymeric stents based
on poly(L-lactide-co-glycolide) (PLGA) in the bile duct was evaluated. The PLGA samples were
synthesized in various molar ratios of lactide (LA) and glycolide (GA) (ratios of LA/GA: 88/12, 80/20,
71/29, 60/40, 50/50). Polymers were processed into circular tubing with parameters of 40 mm length, 10
mm outer diameter, and a wall thickness of about 2 mm. The stents were placed into human bile to
determine the degradation behavior in vitro. Changes in composition, mass loss, molecular weight
configuration, morphology, and water uptake were observed. Copolymers were prepared by ring
opening copolymerization of LA and GA with a catalyst (stannous octoate—Sn(Oct)2, 95%) and used
for stent preparation with a length of 40 mm, an outer diameter of 10 mm, and an inner diameter of 6
mm. Stents with various molar ratios were placed in glass bottles filled with 20 mL bile of clinical
patients. The samples were incubated at 37 ◦C under the oscillation of bile for twenty days. The bile
was replaced every day, and the samples were taken out from the bile every two days. The samples
were cleaned using distilled water and dried under vacuum at room temperature. The PLGA stents
(LA/GA = 71/29) (Figure 10) displayed a suitable duration and degradation behavior for in vivo tests.
Thus, they were sterilized and implanted in adult male Wistar rats. Five rats were sacrificed every
week to examine the degradation state of the stents within a nine-week period.
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Figure 10. Optical images of PLGA stents in different degradation stages (days) in bile at 37 ◦C in vitro.
Lactic acid/glycolic acid (LA/GA) (a) of 50/50; (b) 6 /4 ; (c) 71/29; (d) 80/20; an (e) 88/12, reproduced
from [144] with permission from El evier, 2019.
In vitr experiments revealed a change in the color of the stents from origin lly tra slucent t
yellowish. The color change was due to water and bile abso ption. After several days, the stents
were slightly expanded, but the functions of the stents we maintained. Later, stents were deformed
and crack d, de en ing on the copolymer composi ion (PLGA 50/50 after six days, PLGA 60/40 after
sixteen days, PLGA 71/29 after twenty days). Another two samples preserved the shape, but they
were more stiff and brittle after twenty ays. Tests of PLGA stents on animals were carried out based
on in vitr t sts (71/29). It was observed that the stents were expanded in two weeks. They became
d formed at three weeks, b t the fu ctions of the stents were maintained. The stents disappeared
com letely after five w eks of surg ry. The study has shown that a bio gradable stent made of PLA
and PGA is suitable for short-term use [144].
I another tudy [145], self- xpanding biodegradable stents were used in a porcin model of
biliary st nosis. The stents were prepare from a copolymer consist d of L-lactide and D-lactide (96:4).
D-lactide was used for polyme crystallinity decrease and to accelerate the absorption rate. Stents were
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applied to pigs for six months, and the study concluded that no clinical evidence of biliary obstruction
appeared in this study. The study found that the bio absorbable biliary stent is suitable for endoscopic
application and for approximately six months [145].
In one study [146], an application of a biodegradable polymer stent for the repair and reconstruction
of the bile duct was investigated. PLGA in ratio LA/GA 80/20 was used for copolymer preparation.
Copolymer was treated in a circular tube and studied to determine in vitro degradation behavior in the
bile. Copolymer tubes were further used for tests in dogs′ biliary systems. The obtained results showed
that the PLGA stents exhibited the required biomedical properties. They spontaneously disappeared
from bile duct after four or five weeks. The biodegradation time was sufficiently long for the repair
and reconstruction of the bile duct [146].
In another study [147], helical PLLA stents were used for in vivo and in vitro tests. For in vivo
tests, canine models with injuries of bile duct were used, and a transection of the common bile duct
was performed. Duct to duct anastomosis was performed using helical PLLA biodegradable stents.
Characterization of PLLA stents was performed after three months. PE and PLLA membranes were
inserted into human bile to follow in vitro study. After two months, samples were withdrawn and
observed using SEM. The results showed that biodegradable stents had a good self-clearing effect to
clear away the attached sludge as well as sufficient biocompatibility. The biodegradation provides the
stent self-clearing effect which prevents an attachment of bile sludge. The self-clearing property could
extend applicability of the stent in the bile duct [147].
Polycaprolactone, Polyglycolide, and Polydioxanone Stents
PCL is a well-known polymer that is attractive to the biomedical research community due to its
structural stability, biocompatibility, long biodegradability time, and capacity to form blends with
a many other polymers. One of the first PCL materials was synthesized in the 1930s [148], and
first studies were focused on drug delivery and surgical threads. In the early 1990s, interest in PCL
began to grow again, by the development of tissue engineering, which deals with the regeneration,
repair and building of new tissues or organs, by combining knowledge about cells from biology
and medicine [149–151]. Nowadays, there are many PCLs with very different properties for many
medical applications [152]. PCL is combined with other polymers to form copolymers, which have
better properties than PCL itself. Other biodegradable polymers are used for copolymer preparation,
polymers such as polydioxanone (PDO), polylactide (PLA) or polygycolide (PGA). Combinations
of these polymers bring better properties to the resultant material, such as biodegradability or
healing promotion.
In the study [153], a copolymer of PCL and PLA reinforced with PGA fibres was used for
regenerating the tube of a bile duct. A bioabsorbable copolymer was seeded with autologous bone
marrow cells which had been removed from the swine sternum. After one hour, stents were implanted
into the pigs from which bone marrow cells had been taken. Six months after implantation, all pigs were
alive and gaining weight without signs of jaundice or icterus. They were sacrificed, and histological
and macroscopical observation of the bile duct showed that the neo-bile duct was practically similar to
the native common bile duct in morphology. The results showed that the polymeric stent was replaced
by an extra hepatic bile duct, carrying bile to the duodenum without any leakage in the peritoneal
cavity while preserved its tubular form in the short-term following implantation [153].
Braided stents of PDO with a length of 30 mm and diameters of 6, 8, and 10 mm were used
in another study [154]. Stents were placed into the common pigs’ bile ducts and the animals were
clinically monitored daily. The pigs were gradually sacrificed two, eight, thirteen, and twenty weeks
after implantation, and the bile ducts were observed. Neither bile duct obstruction nor postsurgical
complications were observed. The study found that biodegradable PDO-based polymer stents are
suitable for biliary applications with a treatment period of about 13 weeks [154,155].
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5. Challenges for New Materials with Antimicrobial Properties
Infectious diseases are always caused by some kind of microorganism. There are several ways
how the microorganisms can enter a human body, one of them being a biological contamination
of the surface. Biomedical devices and implants are no exception [156,157]. Microbial organisms
can adhere to the implanted surface or to the surface of a biomedical device and produce bacterial
biofilms [77]. A growing colony of microbial organisms causes chronic infections that are very resistant
to antibiotics [156,157]. The solution to this complication is the production of biomedical instruments
and implants that will have lethal antimicrobial properties [158–160].
Antimicrobial (bio)materials are defined as materials that have antimicrobial properties and a
resistance to infection. These materials are also able to be a carrier of species whose main task is to
prevent, treat, or inhibit potential infection [161]. Technological inventions in the nanotechnology
field are continually provided by advanced antimicrobial materials used for medical applications.
At present, intensive efforts are centered on the development of innovative antimicrobial materials
that are made by the physical or chemical modification of surfaces and matrices. This process can
develop materials that are convenient for applications in the medical field and at the same time have
an antimicrobial effect [162].
Antimicrobial activity of a material can be obtained by two different strategies. The first strategy is
to release a chemical or antimicrobial substance from the surface of a material that focuses on bacteria
around the material. The second strategy is antibiotic molecules that do not allow the attachment of
bacteria being grafted onto the surface of the material [163]. Antimicrobial properties can be supplied
by different agents such as silver, gold, copper, zinc, or clay materials and their modifications [164].
Metallic nanoparticles, especially noble metals, are more attractive to scientists because of their unique
electrical, catalytic, and optical properties [165–168]. They have a high surface-to-volume ratio and
strong antibacterial and antimicrobial properties.
The antimicrobial agents are used to modify the biodegradable polymeric materials from which
they are slowly released and prevent the formation of a biofilm on the surface of the polymeric material.
The antimicrobial effect can also be given to the material by a physical surface treatment where bacteria
and other microorganisms are unable to adhere and develop into a biofilm. Other options based on the
physical properties of the surface, such as a roughening or smooth surface, super hydrophobia, etc.,
have also been proposed to prevent bacterial adhesion [169,170].
The research of new antimicrobial agents is important as microorganisms are increasingly resistant
to antibiotics. At present, antibiotic resistance is considered to be one of the biggest health challenges
according to the World Health Organization (WHO) [165,168]. The first confirmation of bacterial
resistance is dated to 1967, when penicillin-resistant Streptococcus pneumonia was described in Australia.
At present, resistance is not limited to a particular strain of bacteria or to a specific antibiotic. The Centers
for Disease Control and Prevention (CDC) noted that more than 70% of all bacterial infections resist at
least one of the major antimicrobial substances commonly used in hospitals [166]. Moreover, antibiotic
resistance is not the only problem for any particular country. Global monitoring data collected
by the WHO have found that approximately 79% of bacteria developed resistance to one or more
antibiotics [167].
5.1. Antimicrobial Agents
5.1.1. Silver
Most attention is drawn to silver nanoparticles, which are currently used in pharmaceutical
products, such as ointments and creams, but also bandages that prevent infection from burns and open
wounds [171–176]. Silver has long been used as an antimicrobial agent that can be used in various
applications [177–185] and which, at a certain concentration, does not show toxicity to the human
organism. Due to the strong antimicrobial nature of silver cations, they are used, for example, for the
production of vascular, urinary, and peritoneal catheters, vascular grafts, surgical sutures, or implants
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for fracture fixation [186]. Silver ions have been shown to counteract many species of pathogens that
may occur during implantation, such as the bacterial strains E. coli, P. aeruginosa, S. epidermidis, S.
aureus, etc. Silver ions are effective against these bacteria because Ag+ ions disrupt the function of
the bacterial cell membrane, metabolic proteins, and enzymes by linking to DNA and thiol groups
in proteins [187,188]. Silver ions accumulate on the surface of the cell membrane of the bacteria,
subsequently altering the permeability of the bacterial membrane, causing considerable membrane
damage [189]. They are used in various forms, such as particles, silver salts, chelates, or fillers in a
matrix [190].
In medical applications, silver nanoparticles (NP) are most commonly used, which exhibit high
bactericidal activity at concentrations that are not toxic to human cells, and also significantly increase
the antimicrobial activity of conventional antibiotics. The physicochemical properties of silver NPs
facilitate interaction with the bacterial membrane. Particle size, shape, and surface play a very
important role [191,192]. One of the most important aspects to determine silver NP interaction with
cells is their size. The smaller the NPs, the larger the ratio of the surface area is to the nanoparticle
volume. This makes it possible for them to interact more with cell membranes than with larger particle
sizes. The most effective NPs of silver include particles in a range of 1–10 nm, which show the highest
antimicrobial activity and simultaneously the fastest interaction with the cell membrane [189,193].
Currently, scientists are dealing with the bacterial resistance to silver. Bacteria exposed to
sub-inhibitory concentrations of silver NP have been found to be able to form a resistance to antibiotic
activity. This is caused by a production of flagellin, a bacterial adhesion protein, that causes the
aggregation of silver NPs to eliminate their antimicrobial effect against Gram-negative bacteria [188].
5.1.2. Copper
Copper ions and their alloys (brass, bronze, copper-nickel, etc.) are also studied for their
antimicrobial properties in a wide range of microorganisms and rapid antimicrobial activity.
The antibacterial and antimicrobial properties of copper are currently used in water purification,
paints, building materials, and the textile industry. Copper has been found to act primarily against
Gram-positive bacteria, such as S. aureus, but is also active against Gram-negative bacteria such as E.
coli [194–197]. Excess of copper accumulates in the body causing severe metabolic dysfunction and
contributes to the development of neurodegenerative diseases. This raises concerns about whether the
amount of doped copper might be safe for medicine uses [198].
5.1.3. Zinc Oxide
Recently, metal oxides were studied for applications as antimicrobial agents. Metal oxides are
inorganic compounds that have strong antimicrobial activity at low concentrations [199]. They are
stable, non-toxic, and may bring mineral elements that are important for the human body [200,201].
Among metal oxides, ZnO demonstrates a significant antimicrobial effect. It inhibits the growth of a
wide spectrum of bacteria [202]. This metal oxide disrupts the integrity of the bacterial membrane
and other cell processes. Particles with a large surface area have stronger antimicrobial activity than
particles with small surfaces [199,203]. Particularly, ZnO NPs with sizes less than 100 nm have strong
antimicrobial activity, better than micro- or macro-sized particles. Researchers have shown that ZnO
NPs have a selective toxicity to bacteria, but exhibit a minimal effect on human cells [199,204,205].
5.1.4. Clay Minerals
Metal ions are good antimicrobial agents, but their application is limited because of potential
environmental problems that could be overwhelmed by toxic metals in the future. For this reason,
other possible materials with low manufacturing costs, high microbial activity, and long service life
are studied [206]. Clay minerals attract attention due to their non-toxicity to the environment and
easy modification by intercalation [207]. They are very interesting materials among others due to
their layered structure in which various organic or inorganic compounds with antimicrobial and
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antibacterial properties can be incorporated. The layered structure (Figure 11) consists of silicate layers
and interlayer spaces into which another compound or guest may be incorporated (intercalation).
The clay minerals such as vermiculite or montmorillonite have a naturally layered structure, and they
are suitable materials for intercalation of wide range of chemicals.Nanomaterials 2019, 9, x FOR PEER REVIEW 19 of 31 
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Intercalation of organic compounds into layered inorganic clay minerals provides an easy
way to prepare organo-inorganic hybrids that have both an inorganic host and organic guest
properties [208]. A variety of antimicrobial agents such as metal ions, hexadecyltrimethylammonium
bromide (HDTMA), hexadecylpyridinium bromide (HDP), or chlorhexidine (CA) have been used as
fillers. They seem to have a great potential for preparation of biodegradable polymeric materials with
antimicrobial properties.
5.1.5. Hydroxyapatite
Natural materials are often researched for medical applications, as they are usually readily
available and environmentally friendly. An example is hydroxyapatite (HA). HA is a naturally
occurring mineral form of calcium apatite, which also occurs in hard human tissues such as bones and
teeth. Currently, HA is broadly used in medicine as modern body implants (teeth, hip joints, bones).
HA is a suitable material for biomedical applications, since it is itself antimicrobial, highly compatible
with the human organism, and supports the growth of th original bone tissue [209]. A disadvantage
of using of hydroxyap tite for the preparation of polymer composite is the mechanically unsuitable
properties of th r sulting material, such as poor strength o inability to biodegradate.
5.1.6. Carbon Nanomaterials
Carbon-based nanomaterials are widely studied for their excellent physicochemical, mechanical
and optical properties. These materials have also been studied in recent years for their antimicrobial
effects [210,211]. Carbon based nanomaterials such as graphene, graphene oxide, reduced graphene
oxide, carbon nanotubes, and others have a specific structure that has partial antimicrobial effects.
Graphene based nanomaterials may also be an excellent carrier of other antimicrobial agents [212–217].
The one with the greatest potential is graphene oxide.
Graphene Oxide with Antimicrobial Agents
Graphene oxide (GO) is a fascinating c rbon nanomaterial. Specifically, graphene oxide is an
oxidized derivati e of graphene. GO contains a large numb r of xygen-containing functional groups
such as hydr xyl and epoxy functional groups localized on the basal carbon lattice and carboxyl groups
at the edges. These functional groups are active sites for functionalization and hybridization using
other materi ls such as metal ions and metal oxides [218].
Some reports describe he v y strong antimicrobial activity of graphene oxide (GO) [213,219].
Some studies have reported that carbon nanomaterials are cytotoxic for bacteria, but cytotoxicity is
dependent on the mount of carbon nanomat rials and their size [213,220]. However, many stud es
show the or re ults of antibacterial tes s; some research has even showed GO support ng the growth
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of bacterial colonies [221]. Graphene oxides have a good biocompatibility. For this reason, it is a
suitable material for antibacterial agent modification.
ZnO/GO composites were prepared by Wang et al. [218], and antimicrobial activity was tested.
The E. coli strain and human HeLa cells were used to study antibacterial activity and cytotoxicity.
The composite showed strong antibacterial activity at low concentrations, which did not threaten
HeLa cells [218].
In another study [222], the antibacterial activity tests of ZnO/graphene composite showed a 100%
inhibition of E. coli in the medium after twelve hours. Antibacterial activity was probably caused by the
physical interactions of graphene with bacterial membranes, which were disturbed. The antibacterial
properties of ZnO may be due to their ability to photocatalytically generate H2O2 and also to penetrate
cells and disrupt the bacterial membrane upon contact with ZnO NPs. Both of these compounds
synergically cooperated and resulted in the significant antibacterial activity [222].
Graphene oxide is a good material for the modification with silver NPs. Connecting the physical
properties of GO and the strong antibacterial activity of Ag NPs may create a very strong antibacterial
material. This assumption was verified in some studies [223–225] in which composites of GO and
silver NPs (GO–Ag) were produced and characterized. The researchers showed excellent antibacterial
activity against the Gram-negative bacterial strain P. aeruginosa. The composite was tested determining
a minimum inhibitory concentration (MIC), and the results showed an antibacterial activity of GO–Ag
nanocomposite between 2.5 and 5.0 µg/mL. Another result confirmed 100% inhibition of P. aeruginosa
cells after one hour [223–225].
Carbon Nanotubes
Carbon nanotubes (CNTs) are formed by graphenic layers containing carbon atoms in
sp2-hybridized state, which are rolled up into hollow, cylindrical arrangement. CNTs were tested
in many studies as carriers of antimicrobial agents such as metal ions or organic compounds. CNTs
enriched with superparamagnetic properties due to iron oxide and antimicrobial due to silver
nanoparticles have been investigated for their antimicrobial properties and for magnetic separation [226].
The nanotubes were tested to treat an aqueous medium containing E. coli. The antimicrobial activity
was confirmed. Superparamagnetic properties were used to prevent the release of silver NP while
maintaining antimicrobial properties [226].
5.1.7. Antimicrobial Polymeric Materials
Various processes are currently used to form antimicrobial polymeric materials. As an example,
the surface functionalization or modification of the filler can be mentioned. Cleavage of functionalized
polymers on the surface of the material can cause antibacterial activity. Some studies deal with the
derivatives of antimicrobial polyhexamethylene guanidine (PHMG) (the salt of stearic acid, sulphanilic
acid salt, and PE wax) that were added to biodegradable materials. PHMG affects the electrical
properties of the surface of the polymer, which subsequently becomes antibacterial [227]. Similarly,
chitosan can be used, which belongs to a group of polycationic polymers that provide bactericidal
activity by interrupting the negative charge of the bacterium membrane which subsequently goes to
the death [228].
When the biodegradable polymer is modified with antibacterial filler, such as silver or modified
clay material, by progressively degrading the polymer, the antibacterial component is released and
subsequently causes the death of the microorganisms. The polymer product should perform its
function throughout the treatment, while at the same time it should gradually degrade and release the
antibacterial agent [229].
Antimicrobial peptides have evolved as part of the immune system of a variety of organisms,
including humans, and, as their name suggests, are able to kill pathogenic microorganisms such
as bacteria, yeasts, or viruses quickly and effectively [230,231]. Antimicrobial peptides act using
a mechanism that allows them to act only on pathogenic microorganisms while not harming the
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cells of the human body. This selectivity is due to the differences in the cell structure. Bacterial
cells have membranes composed of phospholipids bearing a negative charge (phosphatidylglycerol,
phosphatidylserine, and cardiolipin). These, together with other surface structures (the cell wall in
Gram-negative or lipopolysaccharide in Gram-negative bacteria), give the cells an overall negative
charge, thereby electrostatically attracting cationic antimicrobial peptides. In contrast, human (animal)
cells contain rather neutral phospholipids (phosphatidylcholine and phosphatidylethanolamine) and
cholesterol in their membranes, which additionally stabilizes the membrane. Antimicrobial peptides
interact with the bacterial membrane, immerse in it with their hydrophobic portion and form pores (or
otherwise interfere with its integrity), leading to the release of vital substances from the cell and its
death. There is, however, also a group of antimicrobial peptides that do not break the membrane, only
pass through it inside the cell, and block some of the metabolic processes. Importantly, antimicrobial
peptides act rapidly, on the order of tens of minutes, and rather by a physical mechanism across the
cell surface, so microbes are unlikely to develop resistance to them [232–236].
6. Conclusions
Stenting is a breakthrough medical method for restoring body fluid flow in various body ducts.
One of the main problems with their use is the need to remove them from the body for a variety of
reasons, such as clogging due to biofilm formation, infection due to the presence of a biofilm, but
also due to migration in the body or termination of the treatment process. Removal is performed by
surgical intervention, which can endanger a patient’s life. The solution to these problems may be
biodegradable polymeric materials that progressively disintegrate into basic components that the body
can break down. Simultaneously, biodegradable polymers can be easily modified with antimicrobial
agents, drugs, or antibiotics to prevent the formation and growth of a biofilm on their surface and
the development of infectious diseases. The antimicrobial agents are slowly released when the stent
is degraded and prevent bacteria and microorganisms from adhering to the stent surface, thereby
avoiding biofilm formation and subsequent stent clogging. There are many antimicrobial agents with
a well described effect. However, their usage is complicated by many factors, such as specific effects
only for selected bacteria and other microorganisms, the limited period of antimicrobial agent release,
the possible toxic effect on the human body, or the environment. The preparation of new efficient
materials which can be based on biodegradable polymers containing one antimicrobial agent or their
combination with a wide range of antimicrobial effects is still a challenge.
Funding: This research was funded by MSMT projects No. CZ.02.1.01/0.0/0.0/17\_049/0008441 "Innovative
Therapeutic Methods of Musculoskeletal System in Accident Surgery" within the Operational Programme
Research, Development, and Education financed by the European Union and by the state budget of the Czech
Republic; SP2019/23 Development of biocompatible nanocomposite materials with antimicrobial effects and CSIC
with the cooperation project i-LINK1191 Graphene-based hybrid materials as antimicrobial systems effective
against antibiotic resistant bacteria.
Acknowledgments: We thank Mark Landry for his supervision in English grammar.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Góra, A.; Pliszka, D.; Mukherjee, S.; Ramakrishna, S. Tubular tissues and organs of human body—Challenges
in regenerative medicine. J. Nanosci. Nanotechnol. 2016, 16, 19–39. [CrossRef] [PubMed]
2. He, X.; Fu, W.; Zheng, J. Cell sources for trachea tissue engineering: Past, present and future. Regen. Med.
2012, 7, 851–863. [CrossRef] [PubMed]
3. McMahon, S.; Bertollo, N.; Cearbhaill, E.D.O.; Salber, J.; Pierucci, L.; Duffy, P.; Dürig, T.; Bi, V.; Wang, W.
Bio-resorbable polymer stents: A review of material progress and prospects. Prog. Polym. Sci. 2018, 83,
79–96. [CrossRef]
4. Carey, F.A.; Sheppard, M.N. Diseases of blood vessels. Surgery 2018, 36, 259–264. [CrossRef]
Nanomaterials 2019, 9, 1548 21 of 31
5. Welch, T.R.; Nugent, A.W.; Veeram Reddy, S.R. Biodegradable stents for congenital heart disease. Interv.
Cardiol. Clin. 2019, 8, 81–94. [CrossRef]
6. Meraj, P.M.; Jauhar, R.; Singh, A. Bare metal stents versus drug eluting stents: Where do we stand in 2015?
Curr. Treat. Options Cardiovasc. Med. 2015, 17, 39. [CrossRef]
7. Iqbal, J.; Gunn, J.; Serruys, P.W. Coronary stents: Historical development, current status and future directions.
Br. Med. Bull. 2013, 106, 193–211. [CrossRef]
8. Holm, A.N.; De la Mora Levy, J.G.; Gostout, C.J.; Topazian, M.D.; Baron, T.H. Self-expanding plastic stents in
treatment of benign esophageal conditions. Gastrointest. Endosc. 2008, 67, 20–25. [CrossRef]
9. Testoni, P.A.; Testoni, P.A.; Gastroenterology, D. Endoscopic pancreatic duct stent placement for inflammatory
pancreatic diseases. World J. Gastroenterol. 2007, 13, 5971–5978. [CrossRef]
10. Kobayashi, S.; Ueno, M.; Kameda, R.; Moriya, S.; Irie, K.; Goda, Y.; Tezuka, S.; Yanagida, N.; Ohkawa, S.;
Aoyama, T.; et al. Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer
and gastric outlet obstruction. Pancreatology 2016, 16, 1085–1091. [CrossRef]
11. Gerber, T.C.; Fasseas, P.; Lennon, R.J.; Valeti, V.U.; Wood, C.P.; Breen, J.F.; Berger, P.B. Clinical safety of
magnetic resonanceimaging early after coronary artery stent placement. J. Am. Coll. Cardiol. 2003, 42,
1295–1298. [CrossRef]
12. Park, J.; Kim, J.-K.; Park, S.A.; Lee, D.-W. Biodegradable polymer material based smart stent: Wireless
pressure sensor and 3D printed stent. Microelectron. Eng. 2019, 206, 1–5. [CrossRef]
13. Hermawan, H.; Dubé, D.; Mantovani, D. Developments in metallic biodegradable stents. Acta Biomater. 2010,
6, 1693–1697. [CrossRef] [PubMed]
14. Park, S.A.; Lee, S.J.; Lim, K.S.; Bae, I.H.; Lee, J.H.; Kim, W.D.; Jeong, M.H.; Park, J.K. In vivo evaluation and
characterization of a bio-absorbable drug-coated stent fabricated using a 3D-printing system. Mater. Lett.
2015, 141, 355–358. [CrossRef]
15. Died 2017-Institute of Health Information and Statistics of the Czech Republic, 2017. Available online:
https://www.uzis.cz/system/files/demozem2017.pdf (accessed on 30 August 2019).
16. Cassar, A.; Holmes, D.R.; Rihal, C.S.; Gersh, B.J. Chronic coronary artery disease: Diagnosis and management.
Mayo Clin. Proc. 2009, 84, 1130–1146. [CrossRef]
17. Károly, D.; Charalambous, D.; Pogácsás, B.; Micsik, T.; Barile, C.; Casavola, K. Preparation of explanted
coronary stents for investigation of material properties. Mater. Today Proc. 2016, 3, 997–1002. [CrossRef]
18. Tomberli, B.; Mattesini, A.; Baldereschi, G.I.; Di Mario, C. Breve historia de los stents coronarios. Rev. Española
Cardiol. 2018, 71, 312–319. [CrossRef]
19. Rebagay, G.; Bangalore, S. Biodegradable polymers and stents: The next generation? Curr. Cardiovasc. Risk
Rep. 2019, 13, 2–7. [CrossRef]
20. Zanchin, C.; Ueki, Y.; Zanchin, T.; Häner, J.; Otsuka, T.; Stortecky, S.; Koskinas, K.C.; Siontis, G.C.M.;
Praz, F.; Moschovitis, A.; et al. Everolimus-eluting biodegradable polymer versus everolimus-eluting durable
polymer stent for coronary revascularization in routine clinical practice. JACC Cardiovasc. Interv. 2019, 2019,
1–11. [CrossRef]
21. Buiten, R.A.; Ploumen, E.H.; Zocca, P.; Doggen, C.J.M.; Danse, P.W.; Schotborgh, C.E.; Scholte, M.; Stoel, M.G.;
Hartmann, M.; Tjon, R.M.; et al. Thin, very thin, or ultrathin strut biodegradable- or durable-polymer- coated
drug-eluting stents. JACC Cardiovasc. Interv. 2019, 12, 1650–1660. [CrossRef]
22. Windecker, S.; Serruys, P.W.; Wandel, S.; Buszman, P.; Trznadel, S.; Linke, A.; Lenk, K.; Ischinger, T.; Klauss, V.;
Eberli, F.; et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with
durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008,
372, 1163–1173. [CrossRef]
23. Kereiakes, D.J.; Meredith, I.T.; Windecker, S.; Lee Jobe, R.; Mehta, S.R.; Sarembock, I.J.; Feldman, R.L.; Stein, B.;
Dubois, C.; Grady, T.; et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting
coronary stent. Circ. Cardiovasc. Interv. 2015, 8, 1–8. [CrossRef] [PubMed]
24. Staehr, P. ABSORB bioresorbable vascular scaffold system—The 4th revolution in interventional cardiology.
In Proceedings of the 17th Asian Harmonization Working Party Annual Conference, Taipei, Taiwan, 2–6
November 2012.
25. Gogas, B.D. Coronary interventions bioresorbable scaffolds for percutaneous coronary interventions. Glob.
Cardiol. Sci. Pr. 2014, 2014, 409–427.
Nanomaterials 2019, 9, 1548 22 of 31
26. Regazzoli, D.; Leone, P.P.; Colombo, A.; Latib, A. New generation bioresorbable scaffold technologies: An
update on novel devices and clinical results. J. Thorac. Dis. 2017, 9, 979–985. [CrossRef]
27. Capodanno, D. Bioresorbable scaffolds in coronary intervention: Unmet needs and evolution. Korean Circ. J.
2018, 48, 24–35. [CrossRef]
28. Verheye, S.; Ormiston, J.A.; Stewart, J.; Webster, M.; Sanidas, E.; Costa, R.; Costa, J.R.; Chamie, D.;
Abizaid, A.S.; Pinto, I.; et al. A next-generation bioresorbable coronary scaffold system: From bench to first
clinical evaluation. JACC Cardiovasc. Interv. 2014, 7, 89–99. [CrossRef]
29. Nef, H.M.; Wiebe, J.; Foin, N.; Blachutzik, F.; Dörr, O.; Toyloy, S.; Hamm, C.W. A new novolimus-eluting
bioresorbable coronary scaffold: Present status and future clinical perspectives. Int. J. Cardiol. 2017, 227,
127–133. [CrossRef]
30. Serruys, P.W.; Regar, E.; Carter, A.J. Rapamycin eluting stent: The onset of a new era in interventional
cardiology. BMJ 2002, 305–308. [CrossRef]
31. Iqbal, J.; Onuma, Y.; Ormiston, J.; Abizaid, A.; Waksman, R.; Serruys, P. Bioresorbable scaffolds: Rationale,
current status, challenges, and future. Eur. Heart J. 2014, 35, 765–776. [CrossRef]
32. Verheye, S.; Webster, M.; Stewart, J.; Abizaid, A.; Costa, R.; Costa, J.; Yan, J.; Bhat, V.; Morrison, L.; Toyloy, S.;
et al. TCT-563 multi-center, first-in-man evaluation of the myolimus-eluting bioresorbable coronary scaffold:
6-month clinical and imaging results. J. Am. Coll. Cardiol. 2012, 60, B163. [CrossRef]
33. Mattesini, A.; Bartolini, S.; Dini, C.S.; Valente, S.; Parodi, G.; Meucci, F.; Mario, C. Di The DESolve novolimus
bioresorbable Scaffold: From bench to bedside. J. Thorac. Disease 2017, 9, 950–958. [CrossRef] [PubMed]
34. Sreenivas, A. Interventional cardiology indigenous stents: Examining the clinical data on new technologies.
Interv. Cardiol. 2014, 6, 319–333.
35. Zhang, Y.; Li, M.; Wei, L.; Zhu, L.; Hu, S.; Wu, S.; Ma, S.; Gao, Y. Differential protein expression in perfusates
from metastasized rat livers. Proteome Sci. 2013, 11, 37. [CrossRef] [PubMed]
36. Rao, A.S.; Makaroun, M.S.; Marone, L.K.; Cho, J.S.; Rhee, R.; Chaer, R.A. Long-term outcomes of internal
carotid artery dissection. J. Vasc. Surg. 2011, 54, 370–375. [CrossRef]
37. Fiorani, P.; Speziale, F.; Calisti, A.; Misuraca, M.; Zaccagnini, D.; Rizzo, L.; Giannoni, M.F. Endovascular graft
infection: Preliminary results of an international enquiry. J. Endovasc. Ther. 2004, 10, 919–927. [CrossRef]
38. Vögeling, H.; Pinnapireddy, S.R.; Seitz, B.; Bakowsky, U. Indocyanine green loaded PLGA film coated
coronary stents for photo-triggered in situ biofilm eradication. Colloids Interface Sci. Commun. 2018, 27, 35–39.
[CrossRef]
39. Tanaka, Y.; Yoshida, K.; Suetsugu, T.; Imai, T.; Matsuhashi, N.; Yamaguchi, K. Recent advancements in
esophageal cancer treatment in Japan. Ann. Gastroenterol. Surg. 2018, 2, 253–265. [CrossRef]
40. Fuccio, L.; Scagliarini, M.; Frazzoni, L.; Battaglia, G. Development of a prediction model of adverse events
after stent placement for esophageal cancer. Gastrointest. Endosc. 2016, 83, 746–752. [CrossRef]
41. Repici, A.; Conio, M.; De Angelis, C.; Battaglia, E.; Musso, A.; Pellicano, R.; Goss, M.; Venezia, G.; Rizzetto, M.;
Saracco, G. Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory
benign esophageal strictures. Gastrointest. Endosc. 2004, 60, 513–519. [CrossRef]
42. Langer, F.B.; Wenzl, E.; Prager, G.; Salat, A.; Miholic, J.; Mang, T.; Zacherl, J. Management of postoperative
esophageal leaks with the polyflex self-expanding covered plastic stent. Ann. Thorac. Surg. 2005, 79, 398–403.
[CrossRef]
43. Lin, M.; Firoozi, N.; Tsai, C.-T.; Wallace, M.B.; Kang, Y. 3D-printed flexible polymer stents for potential
applications in inoperable esophageal malignancies. Acta Biomater. 2019, 83, 119–129. [CrossRef] [PubMed]
44. Saito, Y. Usefulness of biodegradable stents constructed of poly-l-lactic acid monofilaments in patients with
benign esophageal stenosis. World J. Gastroenterol. 2007, 13, 3977. [CrossRef] [PubMed]
45. Tanaka, T.; Takahashi, M.; Nitta, N.; Furukawa, A.; Andoh, A.; Saito, Y.; Fujiyama, Y.; Murata, K. Newly
developed biodegradable stents for benign gastrointestinal tract stenoses: A preliminary clinical trial.
Digestion 2006, 74, 199–205. [CrossRef] [PubMed]
46. Griffiths, E.A.; Gregory, C.J.; Pursnani, K.G.; Ward, J.B.; Stockwell, R.C. The use of biodegradable (SX-ELLA)
oesophageal stents to treat dysphagia due to benign and malignant oesophageal disease. Surg. Endosc. 2012,
26, 2367–2375. [CrossRef] [PubMed]
47. Imaz-Iglesia, I.; García-Pérez, S.; Nachtnebel, A.; Martín-Águeda, B.; Sánchez-Piedra, C.; Karadayi, B.;
Demirbas¸, A.R. Biodegradable stents for the treatment of refractory or recurrent benign esophageal stenosis.
Expert Rev. Med. Devices 2016, 13, 583–599. [CrossRef] [PubMed]
Nanomaterials 2019, 9, 1548 23 of 31
48. DiMagno, E.P.; Reber, H.A.; Tempero, M.A. AGA technical review on the epidemiology, diagnosis, and
treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999, 117, 1464–1484. [CrossRef]
49. Adler, D. Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents:
Experience in 36 patients. Am. J. Gastroenterol. 2002, 97, 72–78. [CrossRef]
50. Kozarek, R.A.; Ball, T.J.; Patterson, D.J. Metallic self-expanding stent application in the upper gastrointestinal
tract: Caveats and concerns. Gastrointest. Endosc. 1992, 38, 1–6. [CrossRef]
51. Tokar, J.L.; Banerjee, S.; Barth, B.A.; Desilets, D.J.; Kaul, V.; Kethi, S.R.; Pedrosa, M.C.; Pfau, P.R.; Pleskow, D.K.;
Varadarajulu, S.; et al. Drug-eluting/biodegradable stents. Gastrointest. Endosc. 2011, 74, 954–958. [CrossRef]
52. Wong, Y.T.; Brams, D.M.; Munson, L.; Sanders, L.; Heiss, F.; Chase, M.; Birkett, D.H. Gastric outlet obstruction
secondary to pancreatic cancer. Surg. Endosc. Other Interv. Tech. 2002, 16, 310–312. [CrossRef]
53. Wang, Z.; Li, N.; Li, R.; Li, Y.; Ruan, L. Biodegradable intestinal stents: A review. Prog. Nat. Sci. Mater. Int.
2014, 24, 423–432. [CrossRef]
54. Calcagno, P.; Viti, M.; Cornelli, A.; Galli, D.; Urbano, C.D. Intestinal obstruction caused by endometriosis:
Endoscopic stenting and expedited laparoscopic resection avoiding stoma. A case report and review of the
literature. Int. J. Surg. Case Rep. 2018, 44, 75–77. [CrossRef] [PubMed]
55. Sherman, S.; Alvarez, C.; Robert, M.; Ashley, S.W.; Reber, H.A.; Lehman, G.A. Polyethylene pancreatic duct
stent-induced changes in the normal dog pancreas. Gastrointest. Endosc. 1993, 39, 658–664. [CrossRef]
56. Kassab, C.; Prat, F.; Liguory, C.; Meduri, B.; Ducot, B.; Fritsch, J.; Choury, A.D.; Pelletier, G. Endoscopic
management of post-laparoscopic cholecystectomy biliary strictures. Gastroentérologie Clin. Biol. 2006, 30,
124–129. [CrossRef]
57. Piñol, V.; Castells, A.; Bordas, J.M.; Real, M.I.; Llach, J.; Montañà, X.; Feu, F.; Navarro, S. Percutaneous
self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary
obstruction: Randomized clinical trial. Radiology 2002, 225, 27–34. [CrossRef]
58. Schneider, G.; Siveke, J.T.; Eckel, F.; Schmid, R.M. Pancreatic cancer: Basic and clinical aspects. Gastroenterology
2005, 128, 1606–1625. [CrossRef]
59. Lubezky, N.; Konikoff, F.M.; Rosin, D.; Carmon, E.; Kluger, Y.; Ben-Haim, M. Endoscopic sphincterotomy
and temporary internal stenting for bile leaks following complex hepatic trauma. Br. J. Surg. 2006, 93, 78–81.
[CrossRef]
60. Weber, A.; Zellner, S.; Wagenpfeil, S.; Schneider, J.; Gerngross, C.; Baur, D.M.; Neu, B.; Bajbouj, M.; von
Delius, S.; Algül, H.; et al. Long-term follow-up after endoscopic stent therapy for benign biliary strictures. J.
Clin. Gastroenterol. 2014, 48, 88–93. [CrossRef]
61. Lee, J.H.; Ahmed, O. Endoscopic management of pancreatic cancer. Surg. Oncol. Clin. N. Am. 2019, 28,
147–159. [CrossRef]
62. Lee, T.H.; Jung, M.K.; Kim, T.-K.; Pack, C.G.; Park, Y.K.; Kim, S.-O.; Park, D.H. Safety and efficacy of a metal
stent covered with a silicone membrane containing integrated silver particles in preventing biofilm and
sludge formation in endoscopic drainage of malignant biliary obstruction: Phase II pilot study. Gastrointest.
Endosc. 2019, 90, 663–672. [CrossRef]
63. Shroff, S. Polymers as ureteral stents. J. Endourol. 2010, 24, 191–198.
64. Forbes, C.; Scotland, K.B.; Lange, D.; Chew, B.H. Innovations in ureteral stent technology. Urol. Clin. North
Am. 2019, 46, 245–255. [CrossRef] [PubMed]
65. Mah, T.-F.C.; O’Toole, G.A. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001,
9, 34–39. [CrossRef]
66. Brierly, R.D.; Mostafid, A.H.; Kontothanassis, D.; Thomas, P.J.; Fletcher, M.S.; Harrison, N.W. Is transurethral
resection of the prostate safe and effective in the over 80-year-old? Ann. R. Coll. Surg. Engl. 2001, 83, 50–53.
[PubMed]
67. Rutman, M.P. Prostatic Stents. In A Comprehensive Guide to the Prostate: Eastern and Western Approaches for
Management of BPH; Academic Press: Cambridge, MA, USA, 2018; Chapter 19, ISBN 9780128114643.
68. Nordling, J.; Ovesen, H.; Poulsen, A.L. The intraprostatic spiral: Clinical results in 150 consecutive patients.
J. Urol. 1992, 147, 645–647. [CrossRef]
69. Pétas, A.; Vuopio-Varkila, J.; Siitonen, A.; Välimaa, T.; Talja, M.; Taari, K. Bacterial adherence to self-reinforced
polyglycolic acid and self-reinforced poly-lactic acid 96 urological spiral stents in vitro. Biomaterials 1998, 19,
677–681. [CrossRef]
Nanomaterials 2019, 9, 1548 24 of 31
70. Madersbacher, S. Stents for prostatic diseases: Any progress after 25 years? Eur. Urol. 2006, 49, 212–214.
[CrossRef]
71. Davey, M.E.; O’toole, G.A. Microbial biofilms: From ecology to molecular genetics. Microbiol. Mol. Biol. Rev.
2000, 64, 847–867. [CrossRef]
72. O’Toole, G.; Kaplan, H.B.; Kolter, R. Biofilm formation as microbial development. Annu. Rev. Microbiol. 2000,
54, 49–79. [CrossRef]
73. Donlan, R.M.; Costerton, J.W. Biofilms: Survivalmechanisms of clinically relevant microorganisms. Clin.
Microbiol. Rev. 2002, 15, 167–193. [CrossRef] [PubMed]
74. Fletcher, M. Bacterial adhesion: Molecular and ecological diversity. In Wiley Series in Ecological and Applied
Microbiology; John Wiley & Sons: Hoboken, NJ, USA, 1996; p. 361. ISBN 0471021857.
75. Szczotka-Flynn, L.B.; Pearlman, E.; Ghannoum, M. Microbial contamination of contact lenses, lens care
solutions, and their accessories: A literature review. Eye Contact Lens Sci. Clin. Pract. 2010, 36, 116–129.
[CrossRef] [PubMed]
76. Archibald, L.K.; Gaynes, R.P. Hospital-acquired infections in the United States. Infect. Dis. Clin. North Am.
1997, 11, 245–255. [CrossRef]
77. Maria-Litrán, T.; Allison, D.G.; Gilbert, P. An evaluation of the potential of the multiple antibiotic resistance
operon (mar) and the multidrug eﬄux pump acrAB to moderate. J. Antimicrob. Chemother. 2000, 45, 789–795.
[CrossRef]
78. Costerton, J.W. Bacterial biofilms: A common cause of persistent infections. Science 1999, 284, 1318–1322.
[CrossRef]
79. Kuhn, D.M. Comparison of biofilms formed by candidaalbicans and candidaparapsilosis on bioprosthetic
surfaces. Infect. Immun. 2002, 70, 878–888. [CrossRef]
80. Stein, P.D.; Harken, D.E.; Dexter, L. The nature and prevention of prosthetic valve endocarditis. Am. Heart J.
1966, 71, 393–407. [CrossRef]
81. Shah, H.; Bosch, W.; Thompson, K.M.; Hellinger, W.C. Intravascular catheter-related bloodstream infection.
Neurohospitalist 2013, 3, 144–151. [CrossRef]
82. Nickel, J.C.; Costerton, J.W. Bacterial biofilms and catheters: A key to understanding bacterial strategies in
catheter-associated urinary tract infection. Can. J. Infect. Dis. 1992, 3, 261–267. [CrossRef]
83. Song, Z.; Borgwardt, L.; Høiby, N.; Wu, H.; Sørensen, T.S.; Borgwardt, A. Prosthesis infections after orthopedic
joint replacement: The possible role of bacterial biofilms. Orthop. Rev. (Pavia) 2013, 5, 14. [CrossRef]
84. Gibbs, K.; Holzman, I.R. Endotracheal tube: Friend or foe? Bacteria, the endotracheal tube, and the impact of
colonization and infection. Semin. Perinatol. 2012, 36, 454–461. [CrossRef] [PubMed]
85. Molinari, G.; Pugliese, V.; Schito, G.C.; Guzmán, C.A. Bacteria involved in the blockage of biliary stents and
their susceptibility to antibacterial agents. Eur. J. Clin. Microbiol. Infect. Dis. 1996, 15, 88–92. [CrossRef]
[PubMed]
86. Baerlocher, M.O.; Asch, M.R.; Vellahottam, A.; Puri, G.; Andrews, K.; Myers, A. Safety and efficacy of
gastrointestinal stents in cancer patients at a community hospital. Can. J. Surg. 2008, 51, 130-4. [PubMed]
87. Kim, J.H.; Song, H.-Y.; Shin, J.H.; Choi, E.; Kim, T.W.; Lee, S.K.; Kim, B.S. Stent Collapse as a delayed
complication of placement of a covered gastroduodenal stent. Am. J. Roentgenol. 2007, 188, 1495–1499.
[CrossRef] [PubMed]
88. Borowicz, M.R.; Adams, D.B.; Simpson, J.P.; Cunningham, J.T. Management of biliary strictures due to
laparoscopic cholecystectomy. J. Surg. Res. 1995, 58, 86–89. [CrossRef]
89. Christoforidis, E.; Vasiliadis, K.; Goulimaris, I.; Tsalis, K.; Kanellos, I.; Papachilea, T.; Tsorlini, E.; Betsis, D. A
single center experience in minimally invasive treatment of postcholecystectomy bile leak, complicated with
biloma formation. J. Surg. Res. 2007, 141, 171–175. [CrossRef]
90. Baillie, J. Clinical trial report: Endoscopic treatment of postoperative bile duct strictures using multiple
stents: Long-term results. Curr. Gastroenterol. Rep. 2011, 13, 114–116. [CrossRef]
91. Warshaw, A.L.; Castillo, C.F. Pancreatic carcinoma. N. Engl. J. Med. 1992, 326, 455–465. [CrossRef]
92. Ballinger, A.B.; McHugh, M.; Catnach, S.M.; Alstead, E.M.; Clark, M.L. Symptom relief and quality of life
after stenting for malignant bile duct obstruction. Gut 1994, 35, 467–470. [CrossRef]
93. Cubiella, J.; Castells, A.; Fondevila, C.; Sans, M.; Sabater, L.; Navarro, S.; Fernández-Cruz, L. Prognostic factors
in nonresectable pancreatic adenocarcinoma: A rationale to design therapeutic trials. Am. J. Gastroenterol.
1999, 94, 1271. [CrossRef]
Nanomaterials 2019, 9, 1548 25 of 31
94. Salgado, S.M.; Gaidhane, M.; Kahaleh, M. Endoscopic palliation of malignant biliary strictures. World J.
Gastrointest. Oncol. 2016, 8, 240. [CrossRef] [PubMed]
95. Donelli, G.; Guaglianone, E.; Di Rosa, R.; Fiocca, F.; Basoli, A. Plastic biliary stent occlusion: Factors involved
and possible preventive approaches. Clin. Med. Res. 2007, 5, 53–60. [CrossRef] [PubMed]
96. Rejchrt, S.; Kopacova, M.; Brozik, J.; Bures, J. Biodegradable stents for the treatment of benign stenoses of the
small and large intestines. Endoscopy 2011, 43, 911–917. [CrossRef] [PubMed]
97. Zuber-Jerger, I.; Hempel, U.; Rockmann, F.; Klebl, F. Temporary stent placement in 2 cases of aortoesophageal
fistula. Gastrointest. Endosc. 2008, 68, 599–602. [CrossRef]
98. Pfau, P.R.; Pleskow, D.K.; Banerjee, S.; Barth, B.A.; Bhat, Y.M.; Desilets, D.J.; Gottlieb, K.T.; Maple, J.T.;
Siddiqui, U.D.; Tokar, J.L.; et al. Pancreatic and biliary stents. Gastrointest. Endosc. 2013, 77, 319–327.
[CrossRef]
99. Ruys, A.T.; Rauws, E.A.; Busch, O.R.C.; Lameris, J.S.; Gouma, D.J.; van Gulik, T.M. Preoperative biliary
drainage. In Hilar Cholangiocarcinoma; Springer: Dordrecht, The Netherlands, 2013; pp. 139–146. ISBN
9789400764736.
100. Weber, A.; Prinz, C.; Gerngro, C.; Ludwig, L.; Huber, W.; Neu, B.; Ebert, M.P.; Meining, A.; Weidenbach, H.;
Schmid, R.M.; et al. Long-term outcome of endoscopic and/or percutaneous transhepatic therapy in patients
with biliary stricture after orthotopic liver transplantation. J. Gastroenterol. 2009, 44, 1195–1202. [CrossRef]
101. Hermann, R.E. Shackelford’s surgery of the alimentary tract. JAMA J. Am. Med. Assoc. 1991, 266, 1576.
[CrossRef]
102. Laasch, H.-U.; Martin, D.F. Management of benign biliary strictures. Cardiovasc. Intervent. Radiol. 2002, 25,
457–466. [CrossRef]
103. Padillo, F.J.; Cruz, A.; Briceño, J.; Martin-Malo, A.; Pera-Madrazo, C.; Sitges-Serra, A. Multivariate analysis
of factors associated with renal dysfunction in patients with obstructive jaundice. Br. J. Surg. 2005, 92,
1388–1392. [CrossRef]
104. Son, J.H.; Kim, J.; Lee, S.H.; Hwang, J.-H.; Ryu, J.K.; Kim, Y.-T.; Yoon, Y.B.; Jang, J.-Y.; Kim, S.-W.; Cho, J.Y.;
et al. The optimal duration of preoperative biliary drainage for periampullary tumors that cause severe
obstructive jaundice. Am. J. Surg. 2013, 206, 40–46. [CrossRef]
105. Bismuth, H.; Majno, P.E. Biliary strictures: Classification based on the principles of surgical treatment. World
J. Surg. 2001, 25, 1241–1244. [CrossRef] [PubMed]
106. Perri, V.; Familiari, P.; Tringali, A.; Boskoski, I.; Costamagna, G. Plastic biliary stents for benign biliary
diseases. Gastrointest. Endosc. Clin. N. Am. 2011, 21, 405–433. [CrossRef] [PubMed]
107. Costamagna, G.; Pandolfi, M. Endoscopic stenting for biliary and pancreatic malignancies. J. Clin.
Gastroenterol. 2004, 38, 59–67. [CrossRef] [PubMed]
108. Van Boeckel, P.G.; Vleggaar, F.P.; Siersema, P.D. Plastic or metal stents for benign extrahepatic biliary strictures:
A systematic review. BMC Gastroenterol. 2009, 9, 96. [CrossRef] [PubMed]
109. Stern, N.; Sturgess, R. Endoscopic therapy in the management of malignant biliary obstruction. Eur. J. Surg.
Oncol. 2008, 34, 313–317. [CrossRef]
110. Isayama, H.; Mukai, T.; Itoi, T.; Maetani, I.; Nakai, Y.; Kawakami, H.; Yasuda, I.; Maguchi, H.; Ryozawa, S.;
Hanada, K.; et al. Comparison of partially covered nitinol stents with partially covered stainless stents
as a historical control in a multicenter study of distal malignant biliary obstruction: The WATCH study.
Gastrointest. Endosc. 2012, 76, 84–92. [CrossRef]
111. Davids, P.H.P.; Groen, A.K.; Rauws, E.A.J.; Tytgat, G.N.J.; Huibregtse, K. Randomised trial of self-expanding
metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992, 340, 1488–1492.
[CrossRef]
112. Yeoh, K.G.; Zimmerman, M.J.; Cunningham, J.T.; Cotton, P.B. Comparative costs of metal versus plastic
biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest. Endosc. 1999, 49,
466–471. [CrossRef]
113. Prat, F.; Chapat, O.; Ducot, B.; Ponchon, T.; Pelletier, G.; Fritsch, J.; Choury, A.D.; Buffet, C. A randomized trial
of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest.
Endosc. 1998, 47, 1–7. [CrossRef]
114. Parviainen, M.; Sand, J.; Harmoinen, A.; Kainulainen, H.; Välimaa, T.; Törmälä, P.; Nordback, I. A new
biodegradable stent for the pancreaticojejunal anastomosis after pancreaticoduodenal resection: In vitro
examination and pilot experiences in humans. Pancreas 2000, 21, 14–21. [CrossRef]
Nanomaterials 2019, 9, 1548 26 of 31
115. Soehendra, N.; Reynders-Frederix, V. Palliative bile duct drainage—A new endoscopic method of introducing
a transpapillary drain. Endoscopy 1980, 12, 8–11. [CrossRef] [PubMed]
116. Swidsinski, A. Bacterial biofilm within diseased pancreatic and biliary tracts. Gut 2005, 54, 388–395.
[CrossRef] [PubMed]
117. Catalano, M.F.; Geenen, J.E.; Lehman, G.A.; Siegel, J.H.; Jacob, L.; McKinley, M.J.; Raijman, I.; Meier, P.;
Jacobson, I.; Kozarek, R.; et al. “Tannenbaum” Teflon stents versus traditional polyethylene stents for
treatment of malignant biliary stricture. Gastrointest. Endosc. 2002, 55, 354–358. [CrossRef] [PubMed]
118. Sung, J.Y.; Leung, J.W.C.; Shaffer, E.A.; Lam, K.; Costerton, J.W. Bacterial biofilm, brown pigment stone and
blockage of biliary stents. J. Gastroenterol. Hepatol. 1993, 8, 28–34. [CrossRef] [PubMed]
119. Van Berkel, A.M.; Boland, C.; Redekop, W.K.; Bergman, J.J.G.H.M.; Groen, A.K.; Tytgat, G.N.J.; Huibregtse, K.
A Prospective randomized trial of teflon versus polyethylene stents for distal malignant biliary obstruction.
Endoscopy 1998, 30, 681–686. [CrossRef] [PubMed]
120. England, R.E.; Martin, D.F.; Morris, J.; Sheridan, M.B.; Frost, R.; Freeman, A.; Lawrie, B.; Deakin, M.; Fraser, I.;
Smith, K. A prospective randomised multicentre trial comparing 10 Fr Teflon Tannenbaum stents with 10 Fr
polyethylene Cotton-Leung stents in patients with malignant common duct strictures. Gut 2000, 46, 395–400.
[CrossRef]
121. Terruzzi, V.; Comin, U.; De Grazia, F.; Toti, G.L.; Zambelli, A.; Beretta, S.; Minoli, G. Prospective randomized
trial comparing Tannenbaum Teflon and standard polyethylene stents in distal malignant biliary stenosis.
Gastrointest. Endosc. 2000, 51, 23–27. [CrossRef]
122. Speer, A.G.; Cotton, P.B.; MacRae, K.D. Endoscopic management of malignant biliary obstruction: Stents of
10 French gauge are preferable to stents of 8 French gauge. Gastrointest. Endosc. 1988, 34, 412–417. [CrossRef]
123. Pedersen, F.M. Endoscopic management of malignant biliary obstruction is stent size of 10 french gauge
better than 7 french gauge? Scand. J. Gastroenterol. 1993, 28, 185–189. [CrossRef]
124. Huibregtse, K.; Haverkamp, H.J.; Tytgat, G.N. Transpapillary positioning of a large 3.2 mm biliary
endoprosthesis. Endoscopy 1981, 13, 217–219. [CrossRef]
125. Weber, A.; Mittermeyer, T.; Wagenpfeil, S.; Schmid, R.M.; Prinz, C. Self-expanding metal stents versus
polyethylene stents for palliative treatment in patients with advanced pancreatic cancer. Pancreas 2009, 38,
e7–e12. [CrossRef] [PubMed]
126. Leong, Q.W.; Shen, M.L.; Au, K.W.; Luo, D.; Lau, J.Y.; Wu, J.C.; Chan, F.K.; Sung, J.J. A prospective, randomized
study of the patency period of the plastic antireflux biliary stent: An interim analysis. Gastrointest. Endosc.
2016, 83, 387–393. [CrossRef] [PubMed]
127. Torki, M.M.; Hassanajili, S.; Jalisi, M.M. Design optimizations of PLA stent structure by FEM and investigating
its function in a simulated plaque artery. Math. Comput. Simul. 2019. [CrossRef]
128. Petrtýl, J.; Bru˚ha, R.; Horák, L.; Zádorová, Z.; Dosedeˇl, J.; Laasch, H.-U. Management of benign intrahepatic
bile duct strictures: Initial experience with polydioxanone biodegradable stents. Endoscopy 2010, 42, E89–E90.
[CrossRef]
129. Itoi, T.; Kasuya, K.; Abe, Y.; Isayama, H. Endoscopic placement of a new short-term biodegradable pancreatic
and biliary stent in an animal model: A preliminary feasibility study (with videos). J. Hepatobiliary Pancreat.
Sci. 2011, 18, 463–467. [CrossRef]
130. Yaszemski, M. Evolution of bone transplantation: Molecular, cellular and tissue strategies to engineer human
bone. Biomaterials 1996, 17, 175–185. [CrossRef]
131. Isotalo, T.; Alarakkola, E.; Talja, M.; Tammela, T.L.J.; Välimaa, T.; Törmälä, P. Biocompatibility testing of a
new bioabsorbable X-ray positive sr-pla 96/4 urethral stent. J. Urol. 1999, 162, 1764–1767. [CrossRef]
132. Poole-Warren, L.A.; Patton, A.J. Introduction to biomedical polymers and biocompatibility. In Biosynthetic
Polymers for Medical Applications; Elsevier: Amsterdam, The Netherlands, 2016; pp. 3–31. ISBN 9781782421139.
133. Baudis, S.; Behl, M.; Lendlein, A. Smart polymers for biomedical applications. Macromol. Chem. Phys. 2014,
215, 2399–2402. [CrossRef]
134. Uhrich, K.E.; Abdelhamid, D. Biodegradable and bioerodible polymers for medical applications. In
Biosynthetic Polymers for Medical Applications; Elsevier: Amsterdam, The Netherlands, 2016; pp. 63–83. ISBN
9781782421139.
135. Lasprilla, A.J.R.; Martinez, G.A.R.; Lunelli, B.H.; Jardini, A.L.; Filho, R.M. Poly-lactic acid synthesis for
application in biomedical devices—A review. Biotechnol. Adv. 2012, 30, 321–328. [CrossRef]
Nanomaterials 2019, 9, 1548 27 of 31
136. Lim, L.-T.; Auras, R.; Rubino, M. Processing technologies for poly(lactic acid). Prog. Polym. Sci. 2008, 33,
820–852. [CrossRef]
137. Liu, H.; Song, W.; Chen, F.; Guo, L.; Zhang, J. Interaction of microstructure and interfacial adhesion on impact
performance of polylactide (PLA) ternary blends. Macromolecules 2011, 44, 1513–1522. [CrossRef]
138. Carrasco, F.; Pagès, P.; Gámez-Pérez, J.; Santana, O.O.; Maspoch, M.L. Processing of poly(lactic acid):
Characterization of chemical structure, thermal stability and mechanical properties. Polym. Degrad. Stab.
2010, 95, 116–125. [CrossRef]
139. Avérous, L. Polylactic Acid: Synthesis, Properties and Applications. In Monomers, Polymers and Composites
from Renewable Resources; Elsevier: Amsterdam, The Netherlands, 2008; pp. 433–450. ISBN 9780080453163.
140. Laukkarinen, J.; Nordback, I.; Mikkonen, J.; Kärkkäinen, P.; Sand, J. A novel biodegradable biliary stent in the
endoscopic treatment of cystic-duct leakage after cholecystectomy. Gastrointest. Endosc. 2007, 65, 1063–1068.
[CrossRef] [PubMed]
141. Laukkarinen, J.; Sand, J.; Leppiniemi, J.; Kellomäki, M.; Nordback, I. A novel technique for
hepaticojejunostomy for nondilated bile ducts: A purse-string anastomosis with an intra-anastomotic
biodegradable biliary stent. Am. J. Surg. 2010, 200, 124–130. [CrossRef]
142. Laukkarinen, J.M.; Sand, J.A.; Chow, P.; Juuti, H.; Kellomäki, M.; Kärkkäinen, P.; Isola, J.; Yu, S.; Somanesan, S.;
Kee, I.; et al. A novel biodegradable biliary stent in the normal duct hepaticojejunal anastomosis: An
18-month follow-up in a large animal model. J. Gastrointest. Surg. 2007, 11, 750–757. [CrossRef]
143. Lämsä, T.; Jin, H.; Mikkonen, J.; Laukkarinen, J.; Sand, J.; Nordback, I. Biocompatibility of a new bioabsorbable
radiopaque stent material (BaSO4 containing poly-L,D-lactide) in the rat pancreas. Pancreatology 2006, 6,
301–305. [CrossRef]
144. Xu, X.; Liu, T.; Zhang, K.; Liu, S.; Shen, Z.; Li, Y.; Jing, X. Biodegradation of poly(l-lactide-co-glycolide) tube
stents in bile. Polym. Degrad. Stab. 2008, 93, 811–817. [CrossRef]
145. Ginsberg, G.; Cope, C.; Shah, J.; Martin, T.; Carty, A.; Habecker, P.; Kaufmann, C.; Clerc, C.; Nuutinen, J.-P.;
Törmälä, P. In vivo evaluation of a new bioabsorbable self-expanding biliary stent. Gastrointest. Endosc. 2003,
58, 777–784. [CrossRef]
146. Xu, X.; Liu, T.; Liu, S.; Zhang, K.; Shen, Z.; Li, Y.; Jing, X. Feasibility of biodegradable PLGA common bile
duct stents: An in vitro and in vivo study. J. Mater. Sci. Mater. Med. 2009, 20, 1167–1173. [CrossRef]
147. Meng, B.; Wang, J.; Zhu, N.; Meng, Q.-Y.; Cui, F.-Z.; Xu, Y.-X. Study of biodegradable and self-expandable
PLLA helical biliary stent in vivo and in vitro. J. Mater. Sci. Mater. Med. 2006, 17, 611–617. [CrossRef]
148. van Natta, F.J.; Hill, J.W.; Carothers, W.H. Studies of polymerization and ring formation. XXIII. 1
ε-caprolactone and its polymers. J. Am. Chem. Soc. 1934, 56, 455–457. [CrossRef]
149. Luciani, A.; Coccoli, V.; Orsi, S.; Ambrosio, L.; Netti, P.A. PCL microspheres based functional scaffolds by
bottom-up approach with predefined microstructural properties and release profiles. Biomaterials 2008, 29,
4800–4807. [CrossRef] [PubMed]
150. Lee, K.H.; Kim, H.Y.; Khil, M.S.; Ra, Y.M.; Lee, D.R. Characterization of nano-structured poly(ε-caprolactone)
nonwoven mats via electrospinning. Polymer (Guildf) 2003, 44, 1287–1294. [CrossRef]
151. Marrazzo, C.; Di Maio, E.; Iannace, S. Conventional and nanometric nucleating agents in poly(ε-caprolactone)
foaming: Crystals vs. bubbles nucleation. Polym. Eng. Sci. 2008, 48, 336–344. [CrossRef]
152. Cama, G.; Mogosanu, D.E.; Houben, A.; Dubruel, P. Synthetic biodegradable medical polyesters. In Science
and Principles of Biodegradable and Bioresorbable Medical Polymers; Elsevier: Amsterdam, The Netherlands, 2017;
pp. 79–105. ISBN 9780081003725.
153. Aikawa, M.; Miyazawa, M.; Okada, K.; Toshimitsu, Y.; Torii, T.; Otani, Y.; Koyama, I.; Ikada, Y. Regeneration
of extrahepatic bile duct—Possibility to clinical application by recognition of the regenerative process. J.
Smooth Muscle Res. 2007, 43, 211–218. [CrossRef]
154. Grolich, T.; Crha, M.; Novotný, L.; Kala, Z.; Hep, A.; Necˇas, A.; Hlavsa, J.; Mitáš, L.; Misík, J. Self-expandable
biodegradable biliary stents in porcine model. J. Surg. Res. 2015, 193, 606–612. [CrossRef]
155. Hellmann, M.; Mehta, S.D.; Bishai, D.M.; Mears, S.C.; Zenilman, J.M. The estimated magnitude and direct
hospital costs of prosthetic joint infections in the United States, 1997 to 2004. J. Arthroplasty 2010, 25, 766–771.
[CrossRef]
156. Hall-Stoodley, L.; Costerton, J.W.; Stoodley, P. Bacterial biofilms: From the natural environment to infectious
diseases. Nat. Rev. Microbiol. 2004, 2, 95–108. [CrossRef]
Nanomaterials 2019, 9, 1548 28 of 31
157. Arciola, C.R.; Campoccia, D.; Montanaro, L. Implant infections: Adhesion, biofilm formation and immune
evasion. Nat. Rev. Microbiol. 2018, 16, 397–409. [CrossRef]
158. Uçkay, I.; Hoffmeyer, P.; Lew, D.; Pittet, D. Prevention of surgical site infections in orthopaedic surgery and
bone trauma: State-of-the-art update. J. Hosp. Infect. 2013, 84, 5–12. [CrossRef]
159. Rojas, K.; Canales, D.; Amigo, N.; Montoille, L.; Cament, A.; Rivas, L.M.; Gil-Castell, O.; Reyes, P.; Ulloa, M.T.;
Ribes-Greus, A.; et al. Effective antimicrobial materials based on low-density polyethylene (LDPE) with zinc
oxide (ZnO) nanoparticles. Compos. Part B Eng. 2019, 172, 173–178. [CrossRef]
160. Sullivan, D.J.; Azlin-Hasim, S.; Cruz-Romero, M.; Cummins, E.; Kerry, J.P.; Morris, M.A. Natural Antimicrobial
Materials for Use in Food Packaging; Elsevier Inc.: Amsterdam, The Netherlands, 2018; ISBN 9780128119822.
161. Lv, W.; Luo, J.; Deng, Y.; Sun, Y. Biomaterials immobilized with chitosan for rechargeable antimicrobial drug
delivery. J. Biomed. Mater. Res. Part A 2013, 101A, 447–455. [CrossRef] [PubMed]
162. Bazaka, K.; Jacob, M.V.; Crawford, R.J.; Ivanova, E.P. Efficient surface modification of biomaterial to prevent
biofilm formation and the attachment of microorganisms. Appl. Microbiol. Biotechnol. 2012, 95, 299–311.
[CrossRef] [PubMed]
163. Vasilev, K.; Cook, J.; Griesser, H.J. Antibacterial surfaces for biomedical devices. Expert Rev. Med. Devices
2009, 6, 553–567. [CrossRef] [PubMed]
164. Schrand, A.M.; Rahman, M.F.; Hussain, S.M.; Schlager, J.J.; Smith, D.A.; Syed, A.F. Metal-based nanoparticles
and their toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2, 544–568. [CrossRef]
165. Davies, J.; Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 2010, 74,
417–433. [CrossRef]
166. Coates, A.; Hu, Y.; Bax, R.; Page, C. The future challenges facing the development of new antimicrobial drugs.
Nat. Rev. Drug Discov. 2002, 1, 895–910. [CrossRef]
167. Fukuda, R.K. Antimicrobial Resistance Global Report on Surveillance; World Health Organization: Cham,
Switzerland, 2014.
168. Piddock, L.J. V The crisis of no new antibiotics-what is the way forward? Lancet Infect. Dis. 2012, 12, 249–253.
[CrossRef]
169. Hasan, J.; Chatterjee, K. Recent advances in engineering topography mediated antibacterial surfaces.
Nanoscale 2015, 7, 15568–15575. [CrossRef]
170. Jaggessar, A.; Shahali, H.; Mathew, A.; Yarlagadda, P.K.D.V. Bio-mimicking nano and micro-structured surface
fabrication for antibacterial properties in medical implants. J. Nanobiotechnol. 2017, 15, 1–20. [CrossRef]
171. Nayak, D.; Pradhan, S.; Ashe, S.; Rauta, P.R.; Nayak, B. Biologically synthesised silver nanoparticles from
three diverse family of plant extracts and their anticancer activity against epidermoid A431 carcinoma. J.
Colloid Interface Sci. 2015, 457, 329–338. [CrossRef] [PubMed]
172. Moghaddam, A.B.; Namvar, F.; Moniri, M.; Tahir, P.M.; Azizi, S.; Mohamad, R. Nanoparticles biosynthesized
by fungi and yeast: A review of their preparation, properties, and medical applications. Molecules 2015, 20,
16540–16565. [CrossRef] [PubMed]
173. Zhang, X.F.; Choi, Y.J.; Han, J.W.; Kim, E.; Park, J.H.; Gurunathan, S.; Kim, J.H. Differential nanoreprotoxicity
of silver nanoparticles in male somatic cells and spermatogonial stem cells. Int. J. Nanomedicine 2015, 10,
1335–1357. [PubMed]
174. Hill, R.T. Plasmonic biosensors. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, 7, 152–168. [CrossRef]
[PubMed]
175. Anjum, S.; Sharma, A.; Tummalapalli, M.; Joy, J.; Bhan, S.; Gupta, B. A novel route for the preparation of
silver loaded polyvinyl alcohol nanogels for wound care systems. Int. J. Polym. Mater. Polym. Biomater. 2015,
64, 894–905. [CrossRef]
176. Ansari, M.A.; Khan, H.M.; Khan, A.A.; Cameotra, S.S.; Alzohairy, M.A. Anti-biofi lm effi cacy of silver
nanoparticles against MRSA and MRSE isolated from wounds in a tertiary care hospital. Indian J. Med.
Microbiol. 2015, 33, 101–109. [CrossRef]
177. Gosheger, G. Silver-coated megaendoprostheses in a rabbit model—An analysis of the infection rate and
toxicological side effects. Biomaterials 2004, 25, 5547–5556. [CrossRef]
178. Maharubin, S.; Nayak, C.; Phatak, O.; Kurhade, A.; Singh, M.; Zhou, Y.; Tan, G. Polyvinylchloride coated
with silver nanoparticles and zinc oxide nanowires for antimicrobial applications. Mater. Lett. 2019, 249,
108–111. [CrossRef]
Nanomaterials 2019, 9, 1548 29 of 31
179. Dutta, P.; Wang, B. Zeolite-supported silver as antimicrobial agents. Coord. Chem. Rev. 2019, 383, 1–29.
[CrossRef]
180. Zheng, K.; Setyawati, M.I.; Leong, D.T.; Xie, J. Antimicrobial silver nanomaterials. Coord. Chem. Rev. 2018,
357, 1–17. [CrossRef]
181. Gao, A.; Chen, H.; Hou, A.; Xie, K. Efficient antimicrobial silk composites using synergistic effects of violacein
and silver nanoparticles. Mater. Sci. Eng. C 2019, 103, 109821. [CrossRef] [PubMed]
182. Thokala, N.; Kealey, D.C.; Kennedy, D.J.; Brady, D.D.B.; Farrell, D.J. Comparative activity of silver-based
antimicrobial composites for urinary catheters. Int. J. Antimicrob. Agents 2018, 52, 166–171. [CrossRef]
[PubMed]
183. Falconer, J.L.; Grainger, D.W. 1.4 Silver antimicrobial biomaterials. Compr. Biomater. II 2017, 1, 79–91.
184. Baygar, T.; Sarac, N.; Ugur, A.; Karaca, I.R. Antimicrobial characteristics and biocompatibility of the surgical
sutures coated with biosynthesized silver nanoparticles. Bioorg. Chem. 2019, 86, 254–258. [CrossRef]
[PubMed]
185. Ontong, J.C.; Paosen, S.; Shankar, S.; Voravuthikunchai, S.P. Eco-friendly synthesis of silver nanoparticles
using Senna alata bark extract and its antimicrobial mechanism through enhancement of bacterial membrane
degradation. J. Microbiol. Methods 2019, 165, 105692. [CrossRef]
186. Song, W.-H.; Ryu, H.S.; Hong, S.-H. Antibacterial properties of Ag (or Pt)-containing calcium phosphate
coatings formed by micro-arc oxidation. J. Biomed. Mater. Res. Part A 2009, 88A, 246–254. [CrossRef]
187. Feng, Q.L.; Wu, J.; Chen, G.Q.; Cui, F.Z.; Kim, T.N.; Kim, J.O. A mechanistic study of the antibacterial effect of
silver ions on Escherichia coli and Staphylococcus aureus. J. Biomed. Mater. Res. 2000, 52, 662–668. [CrossRef]
188. Panácˇek, A.; Kvítek, L.; Smékalová, M.; Vecˇerˇová, R.; Kolárˇ, M.; Röderová, M.; Dycˇka, F.; Šebela, M.;
Prucek, R.; Tomanec, O.; et al. Bacterial resistance to silver nanoparticles and how to overcome it. Nat.
Nanotechnol. 2018, 13, 65–71. [CrossRef]
189. Morones, J.R.; Elechiguerra, J.L.; Camacho, A.; Holt, K.; Kouri, J.B.; Ramírez, J.T.; Yacaman, M.J. The
bactericidal effect of silver nanoparticles. Nanotechnology 2005, 16, 2346–2353. [CrossRef]
190. Albers, C.E.; Hofstetter, W.; Siebenrock, K.A.; Landmann, R.; Klenke, F.M. In vitro cytotoxicity of silver
nanoparticles on osteoblasts and osteoclasts at antibacterial concentrations. Nanotoxicology 2013, 7, 30–36.
[CrossRef]
191. Agnihotri, S.; Mukherji, S.; Mukherji, S. Size-controlled silver nanoparticles synthesized over the range 5–100
nm using the same protocol and their antibacterial efficacy. RSC Adv. 2014, 4, 3974–3983. [CrossRef]
192. Pal, S.; Tak, Y.K.; Song, J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the
nanoparticle? A study of the gram-negative bacterium Escherichia coli. Appl. Environ. Microbiol. 2007, 73,
1712–1720. [CrossRef] [PubMed]
193. Shang, L.; Nienhaus, K.; Nienhaus, G.U. Engineered nanoparticles interacting with cells: Size matters. J.
Nanobiotechnol. 2014, 12, 1–11. [CrossRef] [PubMed]
194. Mehtar, S.; Wiid, I.; Todorov, S.D. The antimicrobial activity of copper and copper alloys against nosocomial
pathogens and Mycobacterium tuberculosis isolated from healthcare facilities in the Western Cape: An
in-vitro study. J. Hosp. Infect. 2008, 68, 45–51. [CrossRef]
195. Li, K.; Xia, C.; Qiao, Y.; Liu, X. Dose-response relationships between copper and its
biocompatibility/antibacterial activities. J. Trace Elem. Med. Biol. 2019, 55, 127–135. [CrossRef] [PubMed]
196. Prokhorov, E.; España-Sánchez, B.L.; Luna-Bárcenas, G.; Padilla-Vaca, F.; Cruz-Soto, M.E.;
Vázquez-Lepe, M.O.; Kovalenko, Y.; Elizalde-Peña, E.A. Chitosan/copper nanocomposites: Correlation
between electrical and antibacterial properties. Colloids Surfaces B Biointerfaces 2019, 180, 186–192. [CrossRef]
197. Rauf, A.; Ye, J.; Zhang, S.; Shi, L.; Akram, M.A.; Ning, G. Synthesis, structure and antibacterial activity of a
copper(II) coordination polymer based on thiophene-2,5-dicarboxylate ligand. Polyhedron 2019, 166, 130–136.
[CrossRef]
198. Mercer, J.F.B. The molecular basis of copper-transport diseases. Trends Mol. Med. 2001, 7, 64–69. [CrossRef]
199. Brayner, R.; Ferrari-Iliou, R.; Brivois, N.; Djediat, S.; Benedetti, M.F.; Fiévet, F. Toxicological impact studies
based on Escherichia coli bacteria in ultrafine ZnO nanoparticles colloidal medium. Nano Lett. 2006, 6, 866–870.
[CrossRef]
200. Zhang, L.; Jiang, Y.; Ding, Y.; Povey, M.; York, D. Investigation into the antibacterial behaviour of suspensions
of ZnO nanoparticles (ZnO nanofluids). J. Nanoparticle Res. 2007, 9, 479–489. [CrossRef]
Nanomaterials 2019, 9, 1548 30 of 31
201. Sawai, J. Quantitative evaluation of antibacterial activities of metallic oxide powders (ZnO, MgO and CaO)
by conductimetric assay. J. Microbiol. Methods 2003, 54, 177–182. [CrossRef]
202. Jones, N.; Ray, B.; Ranjit, K.T.; Manna, A.C. Antibacterial activity of ZnO nanoparticle suspensions on a
broad spectrum of microorganisms. FEMS Microbiol. Lett. 2008, 279, 71–76. [CrossRef] [PubMed]
203. Applerot, G.; Lipovsky, A.; Dror, R.; Perkas, N.; Nitzan, Y.; Lubart, R.; Gedanken, A. Enhanced antibacterial
activity of nanocrystalline ZnO due to increased ROS-mediated cell injury. Adv. Funct. Mater. 2009, 19,
842–852. [CrossRef]
204. Thill, A.; Flank, A.M. Cytotoxicity of CeO 2 Nanoparticles physico-chemical insight of the cytotoxicity
mechanism. Environ. Sci. Technol. 2006, 40, 6151–6156. [CrossRef] [PubMed]
205. Reddy, K.M.; Feris, K.; Bell, J.; Wingett, D.G.; Hanley, C.; Punnoose, A. Selective toxicity of zinc oxide
nanoparticles to prokaryotic and eukaryotic systems. Appl. Phys. Lett. 2007, 90, 10–13. [CrossRef]
206. Ghaffari-Moghaddam, M.; Hadi-Dabanlou, R. Plant mediated green synthesis and antibacterial activity of
silver nanoparticles using Crataegus douglasii fruit extract. J. Ind. Eng. Chem. 2014, 20, 739–744. [CrossRef]
207. Holešová, S.; Hundáková, M.; Pazdziora, E. Antibacterial kaolinite based nanocomposites. Procedia Mater.
Sci. 2016, 12, 124–129. [CrossRef]
208. Plachá, D.; Rosenbergová, K.; Slabotínský, J.; Kutláková, K.M.; Študentová, S.; Martynková, G.S. Modified
clay minerals efficiency against chemical and biological warfare agents for civil human protection. J. Hazard.
Mater. 2014, 271, 65–72. [CrossRef]
209. Shah, N.J.; Hong, J.; Hyder, M.N.; Hammond, P.T. Osteophilic multilayer coatings for accelerated bone tissue
growth. Adv. Mater. 2012, 24, 1445–1450. [CrossRef]
210. Chen, J.; Peng, H.; Wang, X.; Shao, F.; Yuan, Z.; Han, H. Graphene oxide exhibits broad-spectrum antimicrobial
activity against bacterial phytopathogens and fungal conidia by intertwining and membrane perturbation.
Nanoscale 2014, 6, 1879–1889. [CrossRef]
211. Zou, X.; Zhang, L.; Wang, Z.; Luo, Y. Mechanisms of the antimicrobial activities of graphene materials. J. Am.
Chem. Soc. 2016, 138, 2064–2077. [CrossRef] [PubMed]
212. He, J.; Zhu, X.; Qi, Z.; Wang, C.; Mao, X.; Zhu, C.; He, Z.; Li, M.; Tang, Z. Killing dental pathogens using
antibacterial graphene oxide. ACS Appl. Mater. Interfaces 2015, 7, 5605–5611. [CrossRef] [PubMed]
213. Akhavan, O.; Ghaderi, E. Toxicity of graphene and graphene oxide nanowalls against bacteria. ACS Nano
2010, 4, 5731–5736. [CrossRef] [PubMed]
214. Li, C.; Wang, X.; Chen, F.; Zhang, C.; Zhi, X.; Wang, K.; Cui, D. The antifungal activity of graphene oxide-silver
nanocomposites. Biomaterials 2013, 34, 3882–3890. [CrossRef]
215. Liu, S.; Zeng, T.H.; Hofmann, M.; Burcombe, E.; Wei, J.; Jiang, R.; Kong, J.; Chen, Y. Antibacterial activity of
graphite, graphite oxide, graphene oxide, and reduced graphene oxide: Membrane and oxidative stress.
ACS Nano 2011, 5, 6971–6980. [CrossRef]
216. Li, N.; Zeng, C.; Qin, Q.; Zhang, B.; Chen, L.; Luo, Z. Powerful antibacterial activity of
graphene/nanoflower-like nickelous hydroxide nanocomposites. Nanomedicine 2018, 13, 2901–2916.
[CrossRef]
217. Jaleel, J.A.; Sruthi, S.; Pramod, K. Reinforcing nanomedicine using graphene family nanomaterials. J. Control.
Release 2017, 255, 218–230. [CrossRef]
218. Wang, Y.W.; Cao, A.N.; Jiang, Y.; Zhang, I.; Liu, J.H.; Liu, Y.F.; Wang, H.F. Superior antibacterial activity
of zinc oxide/graphene oxide composites localized around bacteria. ACS Appl. Mater. Interfaces 2014, 6,
2790–2797.
219. Hu, W.; Peng, C.; Luo, W.; Lv, M.; Li, X.; Li, D.; Huang, Q.; Fan, C. Graphene-based antibacterial paper. ACS
Nano 2010, 4, 4317–4323. [CrossRef]
220. Lyon, D.Y.; Brunet, L.; Hinkal, G.W.; Wiesner, M.R.; Alvarez, P.J.J. Antibacterial activity of fullerene water
suspensions (nC 60) is not due to ROS-mediated damage. Nano Lett. 2008, 8, 1539–1543. [CrossRef]
221. Ruiz, O.N.; Fernando, K.A.S.; Wang, B.; Brown, N.A.; Luo, P.G.; McNamara, N.D.; Vangsness, M.; Sun, Y.-P.;
Bunker, C.E. Graphene oxide: A nonspecific enhancer of cellular growth. ACS Nano 2011, 5, 8100–8107.
[CrossRef] [PubMed]
222. Kavitha, T.; Gopalan, A.I.; Lee, K.P.; Park, S.Y. Glucose sensing, photocatalytic and antibacterial properties of
graphene-ZnO nanoparticle hybrids. Carbon NY 2012, 50, 2994–3000. [CrossRef]
Nanomaterials 2019, 9, 1548 31 of 31
223. de Faria, A.F.; Martinez, D.S.T.; Meira, S.M.M.; de Moraes, A.C.M.; Brandelli, A.; Filho, A.G.S.; Alves, O.L.
Anti-adhesion and antibacterial activity of silver nanoparticles supported on graphene oxide sheets. Colloids
Surfaces B Biointerfaces 2014, 113, 115–124. [CrossRef] [PubMed]
224. Liu, L.; Liu, J.; Wang, Y.; Yan, X.; Sun, D.D. Facile synthesis of monodispersed silver nanoparticles on
graphene oxide sheets with enhanced antibacterial activity. New J. Chem. 2011, 35, 1418. [CrossRef]
225. Das, M.R.; Sarma, R.K.; Saikia, R.; Kale, V.S.; Shelke, M.V.; Sengupta, P. Synthesis of silver nanoparticles in an
aqueous suspension of graphene oxide sheets and its antimicrobial activity. Colloids Surfaces B Biointerfaces
2011, 83, 16–22. [CrossRef]
226. Ali, Q.; Ahmed, W.; Lal, S.; Sen, T. Science direct novel multifunctional carbon nanotube containing silver
and iron oxide nanoparticles for antimicrobial applications in water treatment. Mater. Today Proc. 2017, 4,
57–64. [CrossRef]
227. Wojciechowski, K.; Klodzinska, E. Zeta potential study of biodegradable antimicrobial polymers. Colloids
Surfaces A Physicochem. Eng. Asp. 2015, 483, 204–208. [CrossRef]
228. Muñoz-Bonilla, A.; Fernández-García, M. Polymeric materials with antimicrobial activity. Prog. Polym. Sci.
2012, 37, 281–339. [CrossRef]
229. Muñoz-Bonilla, A.; Echeverria, C.; Sonseca, Á.; Arrieta, M.P.; Fernández-García, M. Bio-based polymers with
antimicrobial properties towards sustainable development. Materials (Basel) 2019, 12, 641. [CrossRef]
230. Paris, J.-B.; Seyer, D.; Jouenne, T.; Thébault, P. Various methods to combine hyaluronic acid and antimicrobial
peptides coatings and evaluation of their antibacterial behaviour. Int. J. Biol. Macromol. 2019, 139, 468–474.
[CrossRef]
231. Sharma, D.; Choudhary, M.; Vashistt, J.; Shrivastava, R.; Bisht, G.S. Cationic antimicrobial peptide and its
poly-N-substituted glycine congener: Antibacterial and antibiofilm potential against A. baumannii. Biochem.
Biophys. Res. Commun. 2019, 518, 472–478. [CrossRef] [PubMed]
232. Koehbach, J.; Craik, D.J. The Vast Structural diversity of antimicrobial peptides. Trends Pharmacol. Sci. 2019,
40, 517–528. [CrossRef] [PubMed]
233. Marcocci, M.E.; Amatore, D.; Villa, S.; Casciaro, B.; Aimola, P.; Franci, G.; Grieco, P.; Galdiero, M.;
Palamara, A.T.; Mangoni, M.L.; et al. The amphibian antimicrobial peptide temporin b inhibits in vitro
herpes simplex virus 1 infection. Antimicrob. Agents Chemother. 2018, 62, e02367-17. [CrossRef] [PubMed]
234. Carter, V.; Underhill, A.; Baber, I.; Sylla, L.; Baby, M.; Larget-Thiery, I.; Zettor, A.; Bourgouin, C.; Langel, Ü.;
Faye, I.; et al. Killer bee molecules: Antimicrobial peptides as effector molecules to target sporogonic stages
of plasmodium. PLoS Pathog. 2013, 9, e1003790. [CrossRef] [PubMed]
235. Felício, M.R.; Silva, O.N.; Gonçalves, S.; Santos, N.C.; Franco, O.L. Peptides with dual antimicrobial and
anticancer activities. Front. Chem. 2017, 5, 1–9. [CrossRef]
236. Zasloff, M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of
two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 1987, 84, 5449–5453.
[CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
